1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

PTP-MEG2 regulates quantal size and fusion pore opening through two distinct structural bases and substrates

Yun-Fei Xu^{*#1}, Xu Chen^{#2}, Zhao Yang¹, Peng Xiao¹, Chun-Hua Liu³, Kang-Shuai Li¹, Xiao-Zhen Yang⁴, Yi-Jing Wang¹, Zhong-Liang Zhu⁵, Zhi-Gang Xu⁶, Sheng Zhang⁷, Chuan Wang⁸, You-Chen Song⁹, Wei-Dong Zhao¹⁰, Chang-He Wang¹¹, Zhi-Liang Ji⁴, Zhong-Yin Zhang⁷, Min Cui^{*2}, Jin-Peng Sun^{*1} and Xiao Yu^{*#2}

Affiliations:

¹Key Laboratory Experimental Teratology of the Ministry of Education and Department of Biochemistry and Molecular Biology, Shandong University School of Medicine, 44 Wenhua Xi Road, Jinan, Shandong, 250012, China

²Key Laboratory Experimental Teratology of the Ministry of Education and Department of Physiology, Shandong University School of Medicine, 44 Wenhua Xi Road, Jinan, Shandong, 250012, China

³Department of Physiology, Taishan Medical University, Taian, Shandong 271000, China.

⁴State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361102, Fujian, China

⁵School of Life Sciences, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui 230026, China

⁶Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, School of Life Sciences, Shandong University, Jinan, China

⁷Departments of Medicinal Chemistry and Molecular Pharmacology and of Chemistry, Center for Cancer Research, and Institute for Drug Discovery, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.

⁸Department of Pharmacology, Hebei Medical University, Shijiazhuang, China

⁹Department of Medical Biophysics, University of Toronto, Toronto, ON, M5S 1A8, Canada

¹⁰Department of Developmental Cell Biology, China Medical University, 77 Puhe Road, Shenbei New District, 110122 Shenyang, China.

¹¹Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China

These authors contributed equally to this work

&Lead author

* Corresponding author: Jin-Peng Sun (corresponding author)

E-mail: sunjinpeng@sdu.edu.cn

Xiao Yu (corresponding author)

E-mail: yuxiao@sdu.edu.cn

Min Cui (corresponding author)
E-mail: cuimin@sdu.edu.cn
Yun-Fei Xu (corresponding author)
E-mail: xuyunfei1988@126.com

ABSTRACT

Tyrosine phosphorylation of secretion machinery proteins is a crucial regulatory mechanism for exocytosis. However, the participation of protein tyrosine phosphatases (PTPs) in different exocytosis stages has not been defined. Here we demonstrated that PTP-MEG2 controls multiple steps of catecholamine secretion. Biochemical and crystallographic analyses revealed key residues that the interactions between govern the PTP-MEG2 and NSF-pY⁸³ site, specify PTP-MEG2 substrate selectivity and modulate the fusion of catecholamine-containing vesicles. Unexpectedly, delineation of PTP-MEG2 mutants along with the NSF binding interface revealed that PTP-MEG2 controls the fusion pore opening through non-NSF dependent mechanisms. Utilizing bioinformatics search and biochemical and electrochemical screening approaches, we discovered that PTP-MEG2 regulates the opening and extension of the fusion pore by dephosphorylating the DYNAMIN2-pY¹²⁵ and MUNC18-1-pY¹⁴⁵ site. Further structural and biochemical analysis confirmed the interaction of PTP-MEG2 with MUNC18-1-pY¹⁴⁵ or DYNAMIN2-pY¹²⁵ through a distinct structural basis compared with that of the NSF-pY⁸³ site. Our studies extended mechanistic insights in complex exocytosis processes.

KEY WORDS:

exocytosis, tyrosine phosphorylation, structure, catecholamine, PTP-MEG2

HIGHLIGHTS:

PTP-MEG2 regulates multiple steps of exocytosis.
A crystal structure of the PTP-MEG2/phosphor-NSF-pY⁸³ segment was obtained.
Functional delineation of the PTP-MEG2/NSF interface led to the discovery of new PTP-MEG2 substrates.
PTP-MEG2 regulates fusion pore opening and extension through the DYNAMIN2-pY¹²⁵ site and MUNC18-1 pY¹⁴⁵ site.
The distinct structural basis of the recognition of substrates by PTP-MEG2 allows selective inhibitor design.

INTRODUCTION

Secretion via vesicle exocytosis is a fundamental biological event involved in almost all physiological processes (Dittman and Ryan, 2019; Neher and Brose, 2018; Wu et al., 2014). The contents of secreted vesicles include neuronal transmitters, immune factors, and other hormones (Alvarez de Toledo et al., 1993; Magadmi et al., 2019; Sudhof, 2013). There are three major exocytosis pathways in secretory cells, namely, full-collapse fusion, kiss-and-run, and compound exocytosis, which possess different secretion rates and release amount (Sudhof, 2004). It has previously been reported that the phosphorylation of critical proteins at serine/threonine or tyrosine residues participates in stimulus–secretion coupling in certain important exocytosis processes, for example, the secretion of insulin from pancreatic β cells and the secretion of catecholamine from the adrenal medulla (Laidlaw et al., 2017; Ortsater et al., 2014; Seino et al., 2009). However, the exact roles of protein tyrosine phosphatases (PTPs) in the regulation of key hormone secretion procedures are not fully understood.

The 68-kDa PTP-MEG2, encoded by *ptpn9*, is a non-receptor classical PTP encompassing a unique N-terminal domain with homology to the human CRAL/TRIO domain and yeast Sec14p (Alonso et al., 2004; Cho et al., 2006; Gu et al., 1992; Huynh et al., 2004; Zhang et al., 2016; Zhang et al., 2012). The N-terminal Sec14p homology domain of PTP-MEG2 recognizes specific phospholipids in the membrane structure and is responsible for its specific subcellular location. In secretory immune cells, PTP-MEG2 has been suggested to regulate vesicle fusion via direct dephosphorylation of the pY⁸³ site of N-ethylmaleimide-sensitive fusion protein (NSF) (Huynh et al., 2004). However, many key issues regarding PTP-MEG2-regulated cell secretion remain controversial or even unexplored. For example, it is uncertain whether PTP-MEG2 regulates vesicle exocytosis only within immune cells (Zhang et al., 2016) and only play insignificant roles in other hormone secretion processes. It remains elusive whether PTP-MEG2 regulates vesicle trafficking pathways other than the NSF-mediated vesicle fusion.

Functional characterization of PTP-MEG2 in vivo normally requires a knockout model; however, PTP-MEG2-deficient mice show neural tube and vascular defects, and the lack of PTP-MEG2 is embryonic lethal (Wang et al., 2005). Alternatively, a specific small-molecule inhibitor of PTP-MEG2 has fast response with no compensatory effects, enabling it to serve as a powerful tool to investigate PTP-MEG2 functions (Yu and Zhang, 2018; Zhang et al., 2012). Recently, we have developed a potent and selective PTP-MEG2 inhibitor, Compound 7, that has a K_i of 34 nM and shows at least 10-fold selectivity for PTP-MEG2 over more than 20 other PTPs (Zhang et al., 2012). The application of this selective PTP-MEG2 inhibitor in combination with electrochemical approaches enabled us to reveal that PTP-MEG2 regulates multiple steps of catecholamine secretion from the adrenal medulla by controlling the vesicle size, the release probabilities of individual vesicles and the initial opening of the fusion pore

during exocytosis. Further crystallographic studies of the PTP-MEG2 protein in complex with the pY⁸³-NSF fragment and enzymological kinetic studies captured the transient interaction between PTP-MEG2 and NSF and provided the structural basis for PTP-MEG2 substrate specificity. Interestingly, by delineating the substrate specificity of deficient PTP-MEG2 mutants in the study of catecholamine secretion from primary chromaffin cells, our results suggested that PTP-MEG2 regulates the initial opening of the fusion pore during exocytosis by regulating substrates other than the known NSF through a distinct structural basis. We therefore took advantage of this key knowledge and utilized bioinformatics analysis, GST pull-down screening, enzymological and electrochemical techniques to identify the potential key PTP-MEG2 substrates involved in fusion pore opening. These experiments led to the identification of several new PTP-MEG2 substrates in the adrenal medulla, of which DYNAMIN2-pY¹²⁵ and MUNC18-1-pY¹⁴⁵ are the crucial dephosphorylation sites of PTP-MEG2 in the regulation of initial pore opening and expansion. Further crystallographic analyses and functional assays with MUNC18-1 Y¹⁴⁵ and DYNAMIN2-pY¹²⁵ revealed the mechanism underlying the recognition of MUNC18-1 and DYNAMIN2 by PTP-MEG2 and how these PTP-MEG2-mediated dephosphorylation events regulate fusion pore dynamics.

RESULTS

Phosphatase activity of PTP-MEG2 is required for catecholamine secretion from adrenal glands

Endogenous PTP-MEG2 expression was readily detected in mouse adrenal gland and chromaffin cell line PC12 cells (Supplemental Fig. 1A-B). Because PTP-MEG2 knockout is embryonic lethal (Wang et al., 2005), we therefore applied our newly developed active-site directed and specific PTP-MEG2 inhibitor (Compound 7) to investigate the functional roles of PTP-MEG2 in catecholamine secretion from adrenal glands (Supplemental Fig. 1C). Compound 7 is a potent and cell-permeable PTP-MEG2 inhibitor, with a K_i value of 34 nM and extraordinary selectivity against other phosphatases (Zhang et al., 2012). The administration of either high concentrations of potassium chloride (70 mM) or 100 nM Angiotensin II (AngII) significantly increased the secretion of both epinephrine (EPI) and norepinephrine (NE) from the adrenal medulla as previously reported (Liu et al., 2017; Teschemacher and Seward, 2000), and this effect was specifically blocked by pre-incubation with Compound 7 (400 nM) for 1 hour (Fig. 1A-D). Notably, basal catecholamine secretion also decreased after pre-incubation with Compound 7 (Fig. 1A-D). However, the intracellular catecholamine contents did not change in response to Compound 7 incubation (Supplemental Fig. 1D-E). These results indicate that PTP-MEG2 plays an essential role in catecholamine

secretion from the adrenal medulla.

PTP-MEG2 inhibition reduces the quantal size and the release probabilities of catecholamine secretion from individual vesicles.

We used the carbon fiber electrode (CFE) to characterize the effects of PTP-MEG2 inhibition on the kinetics of catecholamine secretion from primary cultured chromaffin cells (Chen et al., 2005; Harada et al., 2015) (Fig. 1E-F and Supplemental Fig. 1F-G). The Ang II-induced catecholamine secretion was gradually attenuated by increasing the concentration of Compound 7 after pre-incubation with the primary chromaffin cells, from 20% at 100 nM Compound 7 to 80% at 2 μ M Compound 7 (Fig. 1E-F and Supplemental Fig. 1 F-H). We then compared individual amperometric spikes of chromaffin cells pre-incubated with different concentrations of Compound 7 to determine the effect of PTP-MEG2 inhibition on quantal size (total amperometric spike charge) and vesicle release probabilities. The application of PTP-MEG2 inhibitor reduced quantal size, as indicated by statistical analysis of the quantal size distribution and averaged amperometric spike amplitude (Fig. 1G and Supplemental Fig. 1I). Specifically, the peak of the amperometric spikes decreased from 1.1 pC to 0.5 pC after incubation with 400 nM Compound 7 (Fig. 1G). The number of AngII-induced amperometric spikes also significantly decreased in the presence of Compound 7 (Supplemental Fig. 1J).

We then used transmission electron microscopy to examine the location of the large-dense-core vesicles (LDCVs) in the adrenal medulla after incubation with AngII and Compound 7 (Fig. 1H-I and Supplemental Fig. 2A-B). The intracellular distribution of the LDCVs was summarized by 50 nm bins according to their distance from the chromaffin plasma membrane (Fig. 1J). Vesicles with distance less than 50nm were generally considered to be in the docking stage. Here we found that the application of 400 nM Compound 7 significantly decreased the number of docking vesicles in contact with the plasma membrane (Fig. 1J). Moreover, Compound 7 significantly increased the number of LDCVs with a diameter less than 50 nm and decreased the number of LDCVs with a diameter greater than 150 nm (Fig. 1K), consistent with the statistical analysis of the total amperometric spike charge obtained by electrochemical measurements (Supplemental Fig. 1H-M). This change of vesicle size in the adrenal medulla agreed with the functional studies of PTP-MEG2 in immunocytes, which identified that vesicles were excessively larger if PTP-MEG2 was overexpressed (Huynh et al., 2004).

PTP-MEG2 regulates the initial opening of the fusion pore

Generally, the presence of pre-spike foot (PSF) is a common phenomenon preceding large amperometric spikes which indicate catecholamine secretion in chromaffin cells, while stand-alone foot (SAF) is considered to represent “kiss-and-run” exocytosis (Chen et al., 2005). Both PSF and SAF are usually considered as indications of the initial opening of the fusion pore (Alvarez de Toledo et al., 1993; Zhou et al., 1996). In the present study, Compound 7 substantially decreased the PSF frequency from 25% to 3% and attenuated the SAF frequency from 18% to 4% in response to AngII stimulation (Fig. 1L). Consistent with PSF/SAF frequency, the inhibitor Compound 7 also decreased the average duration, amplitude and charge (Supplemental Fig.2C-J)

The crystal structure of the PTP-MEG2/phospho-NSF complex reveals significant structural rearrangements in the WPD loop and β 3-loop- β 4

PTP-MEG2 is known to modulate interleukin-2 secretion in macrophages via dephosphorylation of NSF, a key regulator in vesicle fusion (Huynh et al., 2004). In response to stimulation with either high potassium chloride or AngII, the two stimulators for catecholamine secretion from the adrenal medulla, the tyrosine phosphorylation of NSF increased, indicating that NSF phosphorylation actively participates in catecholamine secretion (Fig. 2A and Supplemental Fig. 3A-B). Moreover, a significant portion of NSF co-localized with PTP-MEG2 in the adrenal medulla upon AngII stimulation, and the substrate-trapping mutant PTP-MEG2-D⁴⁷⁰A interacted with the tyrosine-phosphorylated NSF from the adrenal medulla treated with peroxide (Fig. 2B-D and Supplemental Fig. 3C-3E), suggesting that PTP-MEG2 regulates catecholamine secretion in chromaffin cells through direct dephosphorylation of NSF.

We therefore co-crystallized PTP-MEG2/phospho-NSF-E⁷⁹-pY⁸³-K⁸⁷, and the structure was solved at 1.7 Å resolution (Table 1). The 2Fo-Fc electron density map allowed for the unambiguous assignment of the phospho-NSF-E⁷⁹-pY⁸³-K⁸⁷ in the crystal structure (Fig. 2E-F). Importantly, the binding of phospho-NSF-E⁷⁹-pY⁸³-K⁸⁷ induced substantial conformational changes in both the WPD loop and β 3-loop- β 4 compared to the crystal structure of PTP-MEG2 alone (Barr et al., 2009) (Fig. 2G-H). Specifically, the interaction of the phosphate group of pY⁸³ of NSF with the guanine group of R⁵²¹ of PTP-MEG2 induced rotation of approximately 90 degrees, which resulted in the movement of W⁴⁶⁸ and a traverse of 7 Å of the WPD loop for a closed state (Fig. 2I-J). Unique to the PTP-MEG2/substrate complex, the movement of L⁴⁶⁶ in the WPD loop by 1.7 Å enabled the formation of a new hydrogen bond between its main chain carbonyl group and the side chain of R⁴⁰³ (Fig. 2I-J). The disruption of the salt bridge

between E⁴⁰⁶ and R⁵²¹ also contributed to the new conformational state of the N-terminal of the β 3-loop- β 4 (Fig. 2K-L). The presence of the phosphate in the PTP-MEG2 active site C-terminal to β 3-loop- β 4 caused a 180-degree rotation of the side chain of S⁵¹⁶, allowing its side chain oxygen to form a new hydrogen bond with the main chain carbonyl of group K⁴¹¹ (Fig. 2K-L). This structural rearrangement altered the side chain conformation of K⁴¹¹, which pointed to the solvent region and formed new polar interactions with E⁴⁰⁶ and the carbonyl group of R⁴⁰⁹ (Fig. 2K-L). Moreover, the presence of the phospho-NSF-E⁷⁹-pY⁸³-K⁸⁷ peptide between R⁴⁰⁹ and D³³⁵ disrupted their charge interactions, enabling a movement of the main chain from G⁴⁰⁸ to K⁴¹¹, accompanied by a side chain movement of R⁴¹⁰ and the formation of new polar interactions with the main chain of P³⁷⁸ and C⁴¹² (Fig. 2M-N). These structural rearrangements that occurred in the WPD loop and β 3-loop- β 4 enabled the accommodation of the phospho-substrate of PTP-MEG2 and may be important for its appropriate interactions with its physiological substrates/partners and subsequent activation.

Structural basis of the PTP-MEG2-NSF interaction

The structural analysis identified critical residues for the phospho-substrate recognition by PTP-MEG2 (Fig. 3A). PTP-MEG2 Y³³³ forms extensive hydrophobic interactions with the phenyl ring of pY⁸³ in NSF. Mutation of this residue caused a significant decrease of more than 8-fold in activity for both p-nitrophenyl phosphate (pNPP) and the phospho-NSF-peptide (Fig. 3B-C), suggesting that this residue is important for PTP-MEG2 recognition of all substrates with phenyl rings. N-terminal to pY⁸³, the side chain oxygen of S⁸¹ formed a hydrogen bond with the carbonyl oxygen of the main chain of R³³² of PTP-MEG2. The carbonyl oxygen of the main chain of S⁸¹ formed a hydrogen bond with the amide group of G³³⁴, and L⁸² formed hydrophobic interactions with the side chain of D³³⁵ (Fig. 3A). Specifically, mutation of G³³⁴ to R impaired the activity of PTP-MEG2 towards the NSF-pY⁸³ phospho-peptide but did not affect on its intrinsic phosphatase activity as measured by using pNPP as a substrate, suggesting that G³³⁴ plays an important role in the recognition of the N-terminal conformation of the peptide substrate (Fig. 3B-C and Supplemental Fig. 4A-B).

The D³³⁵ in the pY binding loop of PTP-MEG2 is also critical for determining the peptide orientation of the substrate by forming important hydrogen bonds with the main chain amide and carbonyl groups of pY⁸³ and T⁸⁴ in NSF. Residues C-terminal to NSF-pY⁸³, T⁸⁴ and F⁸⁵ formed substantial hydrophobic interactions with V³³⁶, F⁵⁵⁶, Q⁵⁵⁹, and Y⁴⁷¹ (Fig. 3A). Accordingly, mutations D³³⁵A or Q⁵⁵⁹A showed no significant effects on pNPP activity but substantially decreased their activities towards the phospho-NSF peptide (Fig. 3B-C and

Supplemental Fig. 4A-B). Mutation I⁵¹⁹A caused a decrease in the intrinsic activity of PTP-MEG2 and a further decrease of approximately 256-fold in its ability to dephosphorylate phospho-NSF-peptide. Moreover, Y⁴⁷¹ formed extensive hydrophobic interactions with T⁸⁴ and F⁸⁵ and also a hydrogen bond with the carboxyl group of pY⁸³. Mutation of Y⁴⁷¹ to either A or F greatly reduced its activity towards the phospho-NSF- E⁷⁹-pY⁸³-K⁸⁷ peptide but had few effects on pNPP dephosphorylation. Taken together, the structural analyses and enzymological studies identified G³³⁴, D³³⁵, Y⁴⁷¹, I⁵¹⁹, and Q⁵⁵⁹ as critical residues for the substrate recognition of NSF by PTP-MEG2. Importantly, although none of these residues are unique to PTP-MEG2, the combination of these residues is not identical across the PTP superfamily but is conserved in PTP-MEG2 across different species, highlighting the important roles of these residues in mediating specific PTP-MEG2 functions (Fig. 3D and Supplemental Fig. 5).

Molecular determinants of Q⁵⁵⁹:D³³⁵ for the substrate specificity of PTP-MEG2

The pY+1 pocket is an important determinant of substrate specificity in different PTP superfamily members (Barr et al., 2009; Li et al., 2016; Wang et al., 2014; Yu et al., 2011). The pY+1 pocket of PTP-MEG2 was found to consist of D³³⁵, V³³⁶, F⁵⁵⁶, and Q⁵⁵⁹ (Fig. 4A). Unique to the PTP-MEG2/NSF-E⁷⁹-pY⁸³-K⁸⁷ complex structure, a relatively small T⁸⁴ residue occurred at the pY+1 position, in contrast to L⁹⁹³ in the PTP1B/EGFR-pY⁹⁹² complex structure, D⁷⁶ in the LYP/SKAP-HOM-pY⁷⁵ complex structure, and L¹²⁴⁹ in the PTPN18/phospho-HER2-pY¹²⁴⁸ complex structure (Fig. 4A). Although several PTPs have an equivalent D: Q pair similar to D³³⁵:Q⁵⁵⁹ of PTP-MEG2 determining the entrance of the pY+1 residue into the pY+1 pocket, such as PTP1B, LYP, PTPN18, STEP, PTP-MEG1, SHP1, PTPH1, and SHP2, structural analysis indicated that the C β between Q⁵⁵⁹ and D³³⁵ is the smallest in PTP-MEG2, at least 1 Å narrower than the other PTP structures examined (Fig. 4B). The narrower pY+1 pocket entrance could be a unique feature for substrate recognition by PTP-MEG2.

PTP-MEG2 regulates two different steps of catecholamine secretion through dephosphorylation of different substrates

We then infected primary chromaffin cells with lentivirus encoding wild-type PTP-MEG2 or different mutants for electrochemical investigation of the structure-function relationship of PTP-MEG2 in the regulation of catecholamine secretion (Fig. 5A, Supplemental Fig. 6A-H and Supplemental Fig. 7A-D). In addition to the wild-type PTP-MEG2, we chose 6 PTP-MEG2 mutants, including G³³⁴R, D³³⁵A, Y⁴⁷¹A, Y⁴⁷¹F, I⁵¹⁹A, and Q⁵⁵⁹A, whose positions are determinants of the interactions between PTP-MEG2 and NSF from the pY⁸³-1 position to the

pY⁸³+2 position (Fig. 5B). Cells with approximately 15- fold of overexpressed exogenous PTP-MEG2 wild type or mutants than the endogenous PTP-MEG2 were selected for electrochemical studies (Supplemental Fig. 6E-F). The PTP-MEG2 mutations did not significantly affect its interaction with NSF, suggesting that residues not located within the active site of PTP-MEG2 may also participate in NSF associations (Supplemental Fig. 6G-6H). The overexpression of wild-type PTP-MEG2 significantly increased both the number and amplitude of the amperometric spikes, which are indicators of the release probabilities of individual vesicles and their quantal sizes, respectively (Fig. 5C-E and Supplemental Fig. 7E). In contrast, the expression of G³³⁴R, D³³⁵A, Y⁴⁷¹A, Y⁴⁷¹F, I⁵¹⁹A, and Q⁵⁵⁹A all significantly decreased the quantal size, the release probabilities of individual vesicles, the half- width and the rise rate of each spike (Fig. 5C-E, Supplemental Fig. 7E-F and Supplemental Fig. 7H). However, there was no difference in the rise time between these mutations and the wild type (Supplemental Fig. 7G). These results suggest that the interaction of PTP-MEG2 with NSF is important for controlling vesicle size and the release probability of catecholamine secretion.

Unexpectedly, the PTP-MEG2 mutants showed different effects on the probabilities of both PSF and SAF (Fig. 5F-G). G³³⁴R mutation which disrupted the recognition of the N-terminal conformation of the peptide substrate of PTP-MEG2, and D³³⁵A and Q⁵⁵⁹A, which are the determinants of pY+1 substrate specificity, significantly reduced the AngII-induced foot probabilities. The mutations of I⁵¹⁹ and Y⁴⁷¹, which formed specific interactions with T⁸⁴ and F⁸⁵ of NSF and are determinants of the C-terminal region of the central phospho-tyrosine involved in the substrate specificity of PTP-MEG2, showed no significant effects (Fig. 5B, Fig. 5F-G and Supplemental Fig. 7I-N). These results indicate that PTP-MEG2 regulates the initial opening of the fusion pore via a distinct structural basis from that of vesicle fusion, probably through dephosphorylating other unknown substrates. As D³³⁵A and Q⁵⁵⁹A of PTP-MEG2 maintained the occurrence of the foot probability, the unknown PTP-MEG2 substrate that regulates the fusion pore opening should have a small residue, such as G, A, S, or T at the pY+1 position. Conversely, the unknown PTP-MEG2 substrate should have a less hydrophobic residue at the pY+2 position because Y⁴⁷¹F, Y⁴⁷¹A, and I⁵¹⁹A of PTP-MEG2 had no significant effects on the foot probability.

Identification of new PTP-MEG2 substrates that contributed to the initial opening of the fusion pore

The effects of PTP-MEG2 mutations along the PTP-MEG2/NSF-phospho-segment interface on catecholamine secretion indicated that a PTP-MEG2 substrate other than NSF with distinct sequence characteristics contributes to the regulation of “foot probability” (Fig. 5). We

therefore utilized this key information to search for new potential PTP-MEG2 substrates by bioinformatics methods (Fig. 6A). First, we searched for the keywords “fusion pore”, “secretory vesicle” and “tyrosine phosphorylation” using the functional protein association network STRING and the text mining tool PubTator, which resulted in a candidate list of 54 proteins. Second, we applied UniProt by selecting proteins located only in the membrane or vesicle, which limited the candidates to 28 members. Third, as our experiments were carried out in the adrenal gland, we used the Human Protein Atlas database for filtering to exclude the proteins which is not detectable in adrenal gland, which narrowed the candidate list to 23 proteins. Finally, we exploited the post-translational-motif database PhosphoSitePlus to screen candidate proteins with potential phospho-sites that matched the sequence requirements at both the pY+1 position and the pY+2 position, which are “G, S, A, T, V, P” and “G, A, S, T, C, V, L, P, D, H”, respectively. These positions were further evaluated by surface exposure if a structure was available. The combination of these searches produced 12 candidate lists with predicted pY positions (Fig. 6B) (Supplemental Table 1-3).

To biochemically characterize whether these proteins are substrates of PTP-MEG2, we transfected the plasmids encoding the cDNAs of these candidate proteins into PC12 cells, stimulated the cells with AngII, and performed a pull-down assay with the GST-PTP-MEG2-D⁴⁷⁰A trapping mutant or GST controls. The known PTP-MEG2 substrate NSF was used as a positive control. Notably, six candidates, including PACSIN1, MUNC18-1, VAMP7, SNAP25, DYNAMIN1 and DYNAMIN2 showed specific interactions with PTP-MEG2 after AngII stimulation in PC12 cells (Fig. 6C and Supplemental Fig. 8A-B). Whereas the protein of MUNC18-1, VAMP7, DYNAMIN2 and SNAP25 were readily detected in the adrenal medulla, DYNAMIN1 and PACSIN1 showed substantially lower expression than that in the liver and brain (Supplemental Fig. 8C). Moreover, whereas MUNC18-1, VAMP7 and DYNAMIN2 strongly co-localized with PTP-MEG2 in the adrenal medulla (Fig. 6D-F), the co-localization of SNAP25 and PACSIN1 with PTP-MEG2 was relatively weak (Supplemental Fig. 8D-E). Therefore, MUNC18-1, VAMP7 and DYNAMIN2 are more likely candidate PTP-MEG2 substrates which were further strengthened by the fact that the high potassium chloride- or AngII-stimulated tyrosine phosphorylation of these proteins in the adrenal medulla was significantly dephosphorylated by PTP-MEG2 in vitro (Supplemental Fig. 9A-C, E), whereas the tyrosine phosphorylation of SNAP25 had no obvious change (Supplemental Fig. 9D-E).

PTP-MEG2 regulated the initial opening of the fusion pore through dephosphorylating MUNC18-1- pY¹⁴⁵

The predicted PTP-MEG2 dephosphorylation site on MUNC18-1 (also called STXBP1) is Y¹⁴⁵, which is localized on the β sheet linker and forms extensive hydrophobic interactions with surrounding residues (Hu et al., 2011; Yang et al., 2015) (Fig. 7A and Supplemental Fig. 10A). Moreover, the phenolic-oxygen of Y¹⁴⁵ forms specific hydrogen bonds with the main chain amide of F⁵⁴⁰ and the main chain carbonyl oxygens of I⁵³⁹ and G⁵⁶⁸ (Fig. 7B). These key interactions might be involved in regulating the arrangement of the arc shape of the three domains of MUNC18-1, by tethering the interface between domain 1 and domain 2. The phosphorylation of Y¹⁴⁵ likely abolishes this H-bond network and changes its ability to associate with different snare complexes participating in vesicle fusion procedures (Fig. 7B). Interestingly, a missense mutation of MUNC18-1 Y¹⁴⁵H was found to be associated with early infantile epileptic encephalopathy (Stamberger et al., 2017) (Fig. 7C).

Notably, the Y¹⁴⁵H missense mutation may not be phosphorylated properly. We therefore overexpressed wild-type MUNC18-1, Y¹⁴⁵A, a non-phosphorylatable mutant, Y¹⁴⁵E, a phosphomimetic mutant, Y¹⁴⁵F, a non-phosphomimetic mutant, and the disease-related Y¹⁴⁵H mutant in PC12 cells stimulated with AngII and then examined their abilities to interact with PTP-MEG2 trapping mutant. The GST pull-down results indicated that all MUNC18-1 Y¹⁴⁵ mutations significantly decreased their ability to associate with PTP-MEG2 (Fig. 7D, supplemental Fig. 9G-9H). In contrast, mutation of the predicted phosphorylation sites of SNAP25, the SNAP25-Y¹⁰¹A, had no significant effect on their interactions with PTP-MEG2 (Supplemental Fig. 9F-H). These results suggested that pY¹⁴⁵ is one of the major sites of MUNC18-1 regulated by PTP-MEG2 (Fig. 7D). Moreover, the effects of the mutations of MUNC18-1 and DYNAMIN2 on protein stability were detected in response to CHX treatments. Consequently, the mutations of MUNC18-1 and DYNAMIN2 had no significant influence on the stability (Supplemental Fig. 9I).

We next infected primary chromaffin cells with a lentivirus encoding wild-type MUNC18-1, the MUNC18-1 Y¹⁴⁵-tyrosine phosphorylation-deficient mutant Y¹⁴⁵F, the MUNC18-1 Y¹⁴⁵-tyrosine phosphorylation mimic mutant Y¹⁴⁵E and the disease-related mutant Y¹⁴⁵H. The Y¹⁴⁵E is a phosphorylation mimic mutant of pY¹⁴⁵, which generate a negative charge at this specific site. In contrast, the Y¹⁴⁵F could not be phosphorylated because of lack of the phenolic oxygen. We thus examined the effects of these mutants using primary chromaffin cells harbouring approximately 20~30 folds MUNC18-1 overexpression related to that of endogenous expression levels (Supplemental Fig. 10B-D). Interestingly, either Y¹⁴⁵E or Y¹⁴⁵H significantly reduced the PSF and SAF percentage of catecholamine secretion in response to AngII stimulation, whereas the phosphorylation-deficient mutant Y¹⁴⁵F showed no significant effects on the PSF or SAF percentage compared to that of the wild type (Fig. 7E-G, and Supplemental Fig. 10 and 11).

To further dissect the mechanism underlying the phosphorylation of MUNC18-1 Y¹⁴⁵ as well as the disease-related mutant Y¹⁴⁵H in the regulation of hormone secretion, we compared the interactions of wild-type and mutant MUNC18-1 with the binding partner SYNTAXIN1 (Lim et al., 2013). Importantly, both the phosphorylation mimic mutant MUNC18-1-Y¹⁴⁵E and the disease-related mutant Y¹⁴⁵H significantly impaired the interaction between MUNC18-1 and SYNTAXIN1 (Fig. 7H, Supplemental Figure 11C). The effects of MUNC18-1 phospho-mimic Y¹⁴⁵E or phospho-defective Y¹⁴⁵F mutants on fusion pore dynamics are correlated with the data of their interaction with the SYNTAXIN1, thus indicating that the the binding between the MUNC18-1 and SYNTAXIN1, which was controlled by the phosphorylation status of Y¹⁴⁵ of MUNC18-1, may play an important role in the formation of the foot during catecholamine secretion. In contrast, the dephosphorylation of pY¹⁴⁵ of MUNC18-1 by PTP-MEG2 promoted initial pore opening and fusion. Collectively, these results suggested that the tyrosine phosphorylation of Y¹⁴⁵ impaired the initial opening of the fusion pore in agonist-induced catecholamine secretion in primary chromaffin cells, probably via either disruption of the arc shape of MUNC18-1 or impairing the interaction between MUNC18-1 and Syntaxin1.

PTP-MEG2 regulated the initial opening of the fusion pore through dephosphorylating DYNAMIN2-pY¹²⁵

Except for MUNC18-1, two additional substrates of PTP-MEG2, which are the Y⁴⁵ site of VAMP7 and the Y¹²⁵ site of DYNAMIN2, were confirmed by GST-pull down assay together with specific mutating effects on the corresponding phosphorylation sites (Fig. 7D, supplemental Fig. 9F-H). It was well known that both DYNAMIN1 and DYNAMIN2 are active regulators of pore fusion dynamics, involved in the pore establishment, stabilization, constriction and fission processes (Jones et al., 2017; Shin et al., 2018; Zhao et al., 2016). The dephosphorylation site of DYNAMIN2 by PTP-MEG2, the Y¹²⁵, is located in a β -sheet of DYNAMIN GTPase domain according to the solved DYNAMIN1 structure (PDB ID: 5D3Q). Previous studies have identified that phosphorylation of DYNAMIN close to the G domain significantly increased its GTPase activity, thus promoting endocytosis (Kar et al., 2017). We therefore hypothesized that the phosphorylation of the DYNAMIN2 pY¹²⁵ site increased pore fission by up-regulating its GTPase activity, whereas dephosphorylation of DYNAMIN2 pY¹²⁵ site by PTP-MEG2 reversed it. Consistent with this hypothesis, the primary chromaffin cells transduced by lentivirus encoding DYNAMIN2 wild type and the Y¹²⁵F mutant significantly decreased percentage of the PSF and SAF of catecholamine secretion elicited by AngII, whereas the phosphorylation mimic mutant DYNAMIN2 Y¹²⁵E mutant exhibited significantly more reduction for the PSF and SAF percentage (Fig. 7I-K and Supplemental Fig. 12). It has been established that the DYNAMIN mediated pore fission process is closely correlated with the receptor endocytosis. Here, whereas overexpression of the DYNAMIN2 wild type or Y¹²⁵E phospho-mimic mutant markedly increased the AngII-induced AT1aR endocytosis, the Y¹²⁵F mutant has no significant effect, suggesting DYNAMIN2 Y¹²⁵E is a gain-of-function mutant to

promote the membrane fission (Fig. 7L) (Liu et al., 2017). Consistent with these cellular results, the in vitro GTPase activity further suggested that the phosphorylation of DYNAMIN2 at pY¹²⁵ site up-regulated its activity (Fig. 7M). Moreover, the LS-MS/MS verified the phosphorylation of DYNAMIN2 at pY¹²⁵ site in primary chromaffin cells under AngII stimulation (Fig. 7N, Supplemental Table 4), indicating that DYNAMIN2 pY¹²⁵ phosphorylation occurred under AngII stimulation and participated in the AngII-induced catecholamine secretion.

Molecular mechanisms of the PTP-MEG2/MUNC18-1-pY¹⁴⁵ and PTP-MEG2-DYNAMIN2-pY¹²⁵ interaction

The k_{cat}/K_m of PTP-MEG2 towards a phospho-segment derived from MUNC18-1-pY¹⁴⁵ is very similar to that obtained with a phospho-segment derived from the known substrate pY⁸³ site of NSF (Supplemental Fig. 4A-B and Supplemental Fig. 14). We therefore crystallized the PTP-MEG2 trapping mutant with the MUNC18-1-E¹⁴¹-pY¹⁴⁵-S¹⁴⁹ phospho-segment and determined the complex structure at 2.2 Å resolution (Table 1). The 2Fo-Fc electro-density map allowed the unambiguous assignment of seven residues of the phospho-MUNC18-1-E¹⁴¹-pY¹⁴⁵-S¹⁴⁹ segment in the crystal structure (Fig. 8A). Importantly, comparing with the phospho-NSF-E⁷⁹-pY⁸³-K⁸⁷ segment, the phospho-MUNC18-1-E¹⁴¹-pY¹⁴⁵-S¹⁴⁹ displayed different interaction patterns with the residues in the PTP-MEG2 active site, forming new interactions with R⁴⁰⁹ and R⁴¹⁰ but lost interactions with Y⁴⁷¹ and I⁵¹⁹ (Fig. 8B). Whereas PTP-MEG2 Y⁴⁷¹ formed extensive hydrophobic interactions with NSF-T⁸⁴ and NSF-F⁸⁵, as well as a well-defined hydrogen bond (2.4 Å) with the carbonyl oxygen of NSF-pY⁸³, PTP-MEG2 Y⁴⁷¹ formed only a weaker H-bond with the carbonyl oxygen of MUNC18-1-pY¹⁴⁵ due to a 0.62 Å shift of Y⁴⁷¹ away from the central pY substrate (Fig. 8C and Supplemental Fig. 13A). Similarly, PTP-MEG2 I⁵¹⁹ did not form specific interactions with the MUNC18-1-E¹⁴¹-pY¹⁴⁵-S¹⁴⁹ segment except for the central pY. In contrast, PTP-MEG2 I⁵¹⁹ formed specific hydrophobic interactions with NSF-T⁸⁴ (Fig. 8D and Supplemental Fig. 13B). Consistently, mutations of PTP-MEG2 Y⁴⁷¹A, Y⁴⁷¹F or I⁵¹⁹A significantly decreased the phosphatase activity towards the phospho-NSF-E⁷⁹-pY⁸³-K⁸⁷ segment (Fig. 3C) but had no significant effect on the phospho-MUNC18-1-E¹⁴¹-pY¹⁴⁵-S¹⁴⁹ segment (Fig. 8E and Supplemental Fig. 14). Meanwhile, R⁴⁰⁹A and R⁴¹⁰A mutations substantially decreased the catalytic activity toward phospho-segments derived from both MUNC18-1-pY¹⁴⁵ and DYNAMIN2 pY¹²⁵ sites, indicating that recognition of these substrates was mediated by common residues (Fig. 8F and Supplemental Fig. 14). Notably, the PTP-MEG2 catalytic domain mutations shows no significant effects on the interactions between PTP-MEG2 with the NSF, MUNC18-1 and DYNAMIN2, indicating other domain of PTP-MEG2, such as its FYVE domain, participated into the association of PTP-MEG2 with these proteins (Supplemental Fig. 6G and Supplemental Fig. 13C-F). With CFE, we further demonstrated that R⁴⁰⁹A and R⁴¹⁰A mutations decreased the probability of both PSF and SAF (Fig. 8G, Supplemental Fig. 15). Combined with the results that PTP-MEG2 Y⁴⁷¹A, Y⁴⁷¹F and

I⁵¹⁹A affect only the spike number and amount but show not the foot probability (Fig. 5B-G), these data suggested that PTP-MEG2 regulated intracellular vesicle fusion by modulating the NSF-pY⁸³ phospho-state but regulated the process of vesicle fusion pore initiation by dephosphorylating MUNC18-1 at pY¹⁴⁵ site and DYNAMIN2 at pY¹²⁵ site (Fig. 8H).

DISCUSSION

Posttranslational modifications of secretion machinery proteins are known as powerful ways to regulate exocytosis. In contrast to the well-characterized serine/threonine phosphorylation, the importance of tyrosine phosphorylation in exocytosis has only recently begun to be appreciated (Cijssouw et al., 2014; Gabel et al., 2019; Jewell et al., 2011; Laidlaw et al., 2017; Meijer et al., 2018; Seino et al., 2009). In addition to the phosphorylation of NSF at its pY⁸³ site, recent studies have shown that tyrosine phosphorylation of MUNC18-3 at the pY²¹⁹ and pY⁵²⁷ sites, Annexin-A2 at pY²³, and MUNC18-1 at pY⁴⁷³ actively participates in the vesicle release machinery to explicitly regulate exocytosis processes (Gabel et al., 2019; Jewell et al., 2011; Meijer et al., 2018). The tyrosine phosphorylation at specific sites of the signalling molecule is precisely regulated by protein tyrosine kinases and protein tyrosine phosphatases (Tonks, 2006; Yu and Zhang, 2018). Although tyrosine kinases such as the insulin receptor, Src and Fyn are acknowledged to play critical roles in hormone secretion (Jewell et al., 2011; Meijer et al., 2018; Oakie and Wang, 2018; Soares et al., 2013), only a very few PTPs that regulate the vesicle release machinery have been identified, and the structural basis of how these PTPs selectively dephosphorylate the key tyrosine phosphorylation sites governing exocytosis was unknown. In the current study, we demonstrated that PTP-MEG2 is an important regulator of hormone secretion from the chromaffin cell, using a selective PTP-MEG2 inhibitor in combination with cellular and electrochemical amperometric recording. The current study extended the regulatory role of PTP-MEG2 in various steps of exocytosis in hormone secretion beyond the previously known simple vesicle fusion step of the immune system (Huynh et al., 2004). We then determined the crystal structure of PTP-MEG2 in complex with the pY⁸³ phospho-segment of the NSF, the key energy provider for disassembling fusion-incompetent cis SNARE complexes in the process of vesicle fusion in immunocytes (Huynh et al., 2004). The complex structure not only revealed the structural rearrangement in PTP-MEG2 in response to binding of the substrate NSF, identifying Q⁵⁵⁹:D³³⁵ as the key pair for substrate specificity of the pY+1 site, but also provided clues that PTP-MEG2 regulated the initial opening of the fusion pore through another unknown substrate. Fortunately, we were able to deduce the signature of the pY+1 and pY+2 positions of this unknown substrate by carefully inspecting the PTP-MEG2/phospho-NSF-E⁷⁹-pY⁸³-K⁸⁷ complex structure and analysing the functional data of the PTP-MEG2 interface mutants. Further bioinformatics studies and cellular

and physiological experiments enabled us to discover that PTP-MEG2 regulates the initial opening of the fusion pore by modulating the tyrosine phosphorylation states of the MUNC18-1 at the pY¹⁴⁵ site and the DYNAMIN2 at the pY¹²⁵ site. Therefore, we have revealed that PTP-MEG2 regulates different steps of the exocytosis processes via dephosphorylating distinct substrates. PTP-MEG2 regulates the vesicle size and vesicle-vesicle fusion step by dephosphorylating NSF at its NSF-pY⁸³ site, whereas it regulates the process of LDCV fusion pore initiation and expansion by controlling specific phosphorylation sites of MUNC18-1 and DYNAMIN2. Moreover, our studies highlight that the combination of structural determination and functional delineation of the interface mutants of the protein complex is a powerful approach to characterizing the signalling events and identifying unknown downstream signalling molecules.

Fusion pore opening and expansion is thought to be a complex process requiring the docking of apposed lipid bilayers and involvement of multiple proteins to form a hemi-fusion diaphragm including SNAREs, MUNC18-1, and DYNAMIN (Baker and Hughson, 2016; Hernandez et al., 2012; Jones et al., 2017; Mattila et al., 2015; Sudhof and Rothman, 2009; Zhao et al., 2016). Dissection of the molecular mechanism underlying pore fusion dynamics in exocytosis is challenging because direct observation of this process is difficult to achieve due to the short expansion time and the tiny size of the pore (Baker and Hughson, 2016; Gaisano, 2017; Hong and Lev, 2014). Importantly, the DYNAMINs are key terminators of the fusion pore expansion by scissoring vesicles from the cell membrane (Eitzen, 2003) (Jones et al., 2017; Shin et al., 2018; Zhao et al., 2016). The large scale phosphoproteomic screens have identified multiple tyrosine phosphorylation sites of DYNAMIN, such as that occurring at pY⁸⁰, pY¹²⁵, pY³⁵⁴ and pY⁵⁹⁷ (Ballif et al., 2008) (Mallozzi et al., 2013). Among them, the Y⁵⁹⁷ was a well-studied phosphorylation site of DYNAMIN, which was previously reported to increase self-assembly and GTP hydrolysis in both DYNAMIN1 and 2 (Kar et al., 2017). However, the Y⁵⁹⁷ of DYNAMIN was probably not the target of PTP-MEG2 because the interaction of Y⁵⁹⁷ or A⁵⁹⁷ with PTP-MEG2 exhibited no significant differences. However, the regulation of other tyrosine phosphorylation site, such as pY¹²⁵, as well as how this particular tyrosine phosphorylation participated in a selective secretion process, has not been elucidated. Here, by using pharmacological approach with high selectivity, functional alanine mutagenesis according to structural characterization, combined with bioinformatics, electrochemistry and enzymology, we have demonstrated that PTP-MEG2 negatively regulated the pY¹²⁵ phosphorylation state during the catecholamine secretion, which promoted the cessation of the fusion pore expansion through increasing its GTP activity.

In addition to DYNAMIN, MUNC18-1 and its closely related subfamily members have been demonstrated to participate in several processes during vesicle secretion by interacting with SNAREs, such as docking, priming and vesicle fusion (Chai et al., 2016; Cijssouw et al.,

2014; Fisher et al., 2001; Gulyas-Kovacs et al., 2007; He et al., 2017; Korteweg et al., 2005; Ma et al., 2013; Ma et al., 2015; Meijer et al., 2018; Sitarska et al., 2017). Importantly, the tyrosine phosphorylation of MUNC18-1 at Y⁴⁷³ was recently reported as a key step in modulating vesicle priming by inhibiting synaptic transmission and preventing SNARE assembly (Meijer et al., 2018). In addition, the tyrosine phosphorylation of MUNC18-3 on Y⁵²¹ was essential for the dissociation of MUNC18-3 and SYNTAXIN4 (Umahara et al., 2008). Moreover, the dephosphorylation of MUNC18-1-Y¹⁴⁵ was suggested to be essential in maintaining the association between MUNC18-1 and SYNTAXIN1 (Lim et al., 2013). In the present study, we demonstrated that the MUNC18-1 Y¹⁴⁵E phospho-mimic mutation, but not the non-phosphorylated mutation Y¹⁴⁵F, significantly decreased the PSF and the SAF probability in cultured primary chromaffin cells. Notably, either the Y¹⁴⁵E phospho-mimic mutation or the epileptic encephalopathy associated Y¹⁴⁵H mutant disrupted their interactions with SYNTAXIN1. Structural inspection also suggested that both phosphorylation of Y¹⁴⁵ and Y¹⁴⁵H mutant could destabilize the arc shape of native MUNC18-1. Therefore, it's very likely that either the association of the MUNC18-1 with the SYNTAXIN1 or the maintenance of the arc shape of the MUNC18-1 actively participated in initial pore opening and expansion. Future studies by solving the fusion machinery structures encompassing with MUNC18-1 at different stages with high resolutions, as well as more detailed fusion pore dynamics analysis using in vitro reconstitution system could provide deeper insights for these key events in proe fusion processes. In the present study, the structural analysis of PTP-MEG2 in complex with MUNC18-1-pY¹⁴⁵ and the enzymatic analysis confirmed that PTP-MEG2 regulated two different substrates, the MUNC18-1-pY¹⁴⁵ and the DYNAMIN2-pY¹²⁵ with similar structural features and generated similar effects on fusion pore dynamics. Therefore, our studies exemplified how a PTPase regulated one important physiological process through two different substrates, adding new information of the fusion pore regulation from another aspect.

Notably, the MUNC18-1 Y¹⁴⁵H mutation is a known SNP that is associated with epileptic encephalopathy (Stamberger et al., 2017). Y¹⁴⁵H behaves similarly to the MUNC18-1 phosphorylation mimic mutant Y¹⁴⁵E by disrupting its interaction with SYNTAXIN1 and reducing the probability of PSF elicited by AngII in primary chromaffin cells. This observation provided a clue for the pathological effects of the MUNC18-1 Y¹⁴⁵H mutation. In addition to MUNC18-1, we found that VAMP7 interacted with PTP-MEG2 via their Y⁴⁵ tyrosine phosphorylation site, respectively. DYNAMIN1, PASCIN1 and SNAP25 are also potential PTP-MEG2 substrates depending on specific cellular contexts. The functions of VAMP7 phosphorylation at the Y⁴⁵ site and its dephosphorylation by PTP-MEG2, the interaction of PTP-MEG2 with DYNAMIN1, etc. in the exocytosis process await further investigation.

Finally, by solving the two crystal structures of PTP-MEG2 in complex with two substrates, the phospho-NSF-E⁷⁹-pY⁸³-K⁸⁷ segment and the phospho-MUNC18-1-E¹⁴¹-pY¹⁴⁵-S¹⁴⁹ segment,

we revealed that PTP-MEG2 recognized these functionally different substrates through distinct structural bases. Whereas K⁴¹¹, Y⁴⁷¹ and I⁵¹⁹ contributed most to the selective interaction of PTP-MEG2 with NSF, another set of residues, including R⁴⁰⁹ and R⁴¹⁰, mediated the specific binding of PTP-MEG2 to MUNC18-1 (Fig. 8B). Most importantly, mutating Y⁴⁷¹ and I⁵¹⁹ to A significantly decreased the activity of PTP-MEG2 towards the phospho-NSF-E⁷⁹-pY⁸³-K⁸⁷ segment but not the phospho-MUNC18-1-E¹⁴¹-pY¹⁴⁵-S¹⁴⁹ segment. The biochemical data agreed well with the functional data that PTP-MEG2 Y⁴⁷¹A and I⁵¹⁹A of PTP-MEG2 affected only the vesicle fusion procedure but not the fusion pore opening and expansion processes. These data not only indicate that PTP-MEG2 regulates different steps of exocytosis through different substrates in an explicit temporal and spatial context but also afforded important guidance for the design of selective PTP-MEG2 inhibitors according to the different interfaces between PTP-MEG2 and its substrates to explicitly regulate specific physiological processes, supporting the hypothesis of “substrate-specific PTP inhibitors” (Doody and Bottini, 2014). The design of such inhibitors will certainly help to delineate specific roles of PTP-MEG2 in different physiological and pathological processes.

In conclusion, we have found that PTP-MEG2 regulates two different processes of exocytosis during catecholamine secretion, namely, vesicle fusion and the opening and extension of the fusion pore, through two different substrates with distinct structural bases. We achieved this knowledge by determining the complex structure and performing functional delineation of the protein complex interface mutants. The present study supports the hypothesis that the tyrosine phosphorylation of secretion machinery proteins is an important category of regulatory events for hormone secretion and is explicitly regulated by protein tyrosine phosphatases, such as PTP-MEG2. Dissecting the molecular and structural mechanisms of such modulation processes will provide an in-depth understanding of the exocytosis process and guide further therapeutic development for exocytosis-related diseases, such as epileptic encephalopathy (Stamberger et al., 2017).

METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
NSF Antibody	Proteintech	Cat # 21172-1-AP
NSF Antibody	Santa Cruz	Cat # sc-515043

MUNC18-1 Antibody	Proteintech	Cat # 11459-1-AP
MUNC18-1 Antibody	Proteintech	Cat # 67137-1-lg
VAMP7 Antibody	Proteintech	Cat # 22268-1-AP
VAMP7 Antibody	Santa Cruz	Cat # sc-166394
SNAP25 Antibody	Proteintech	Cat # 60159-1-lg
SNAP25 Antibody	Proteintech	Cat # 14903-1-AP
PACSIN1 Antibody	Proteintech	Cat # 13219-1-AP
SYNTAXIN1a Antibody	Proteintech	Cat # 66437-1-lg
pTyr(PY20) Antibody	Santa Cruz	Cat # sc-508
pTyr(PY99) Antibody	Santa Cruz	Cat # sc-7020
FLAG Antibody	Cell Signaling Technology	Cat # 2368
GAPDH Antibody	Cell Signaling Technology	Cat # 5174
PTP-MEG2 Antibody	R&D Systems	Cat # MAB2668
DYNAMIN1 Antibody	Abcam	Cat # AB52611
DYNAMIN2 Antibody	Abcam	Cat # AB65556
DYNAMIN2 Antibody	Santa Cruz	Cat # sc-166669

Chemicals, Peptides, and Recombinant Proteins

Anti-GST-tag beads	TransGen Biotech Co., Ltd	Cat # DP201
Anti-GFP-tag beads	AlpaLife by KangTi Co., Ltd.	Cat # KTSM1301
Protein A/G-PLUS-Agarose	Santa Cruz	Cat # sc-2003
Ni-NTA Agarose	Thermo Fisher scientific	Cat # R90101
The phospho-peptide of NSF “EVSLpYTFDK”	China Peptides Co., Ltd	N/A
The phospho-peptide of MUNC18-1 “ESQVpYSLDS”	China Peptides Co., Ltd	N/A
The phospho-peptide of DYNAMIN2 “NLRVpYSPHV”	China Peptides Co., Ltd	N/A
Mouse EPI ELISA Kit	Shanghai Jianglai Co.,Ltd	JL11194-48T

Mouse NE ELISA Kit	Shanghai Jianglai Co.,Ltd	JL13969-96T
Angiotensin II (HDRVYIHPF-OH)	China Peptides Co., Ltd	N/A
Compound 7(PTP-MEG2 inhibitor)	Synthesized as previously described (Zhang et al., 2012)	

Experimental Models: Cell Lines

293	ATCC	CRL-1573
293T	ATCC	CRL-3216
PC12	ATCC	CRL-1721

Software and Algorithms

PyMol	Schrödinger	https://www.pymol.org/
CCP4i	Instruct Associate Centre for Integrated Structural Biology	http://www.ccp4.ac.uk/
Phenix	The PHENIX Industrial Consortium	https://www.phenix-online.org
Igor	Fourier Transform	https://www.wavemetrics.com/
Prism	GraphPad	http://www.graphpad.com

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Professor Xiao Yu. (yuxiao@sdu.edu.cn) or Jinpeng Sun (sunjinpeng@bjmu.edu.cn)

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell Culture

The HEK293 cell lines, the 293T cell lines and PC12 cell lines were originally obtained from the American Type Culture Collection (ATCC). The HEK293 cell lines and 293T cell lines were grown in DMEM with 10% FBS (Gibco, Grand Island, NY, US) and 1% penicillin/streptomycin at 37 °C. PC12 cells were maintained at 37 °C in DMEM medium containing 10% FBS (Gibco, US), 5% donor equine serum (Gibco, US) and 1% penicillin/streptomycin.

Constructs

Sequences of PTP-MEG2 catalytic domain were subcloned into PET-15b expression vector with an N-terminal His tag or PGEX-6P-2 expression vector containing an N-terminal GST tag. The mutations of PTP-MEG2 were constructed by the Quikchange kit from Stratagene .

Plasmid	Vehicle information	Tag information
NSF	PCDNA3.1	FLAG
His-PTPMEG2-WT	pET-15b	His
His-PTPMEG2-333Y-A	pET-15b	His
His-PTPMEG2-334G-R	pET-15b	His
His-PTPMEG2-335D-A	pET-15b	His
His-PTPMEG2-471Y-A	pET-15b	His
His-PTPMEG2-471Y-F	pET-15b	His
His-PTPMEG2-519I-A	pET-15b	His
His-PTPMEG2-559Q-A	pET-15b	His
His-PTPMEG2-409R-A	pET-15b	His
His-PTPMEG2-410R-A	pET-15b	His
PCDH-PTPMEG2-WT	PCDH	GFP
PCDH-PTPMEG2-334G-R	PCDH	GFP
PCDH-PTPMEG2-335D-A	PCDH	GFP
PCDH-PTPMEG2-471Y-A	PCDH	GFP
PCDH-PTPMEG2-471Y-F	PCDH	GFP
PCDH-PTPMEG2-519I-A	PCDH	GFP
PCDH-PTPMEG2-559Q-A	PCDH	GFP
PCDH-PTPMEG2-409R-A	PCDH	GFP
PCDH-PTPMEG2-410R-A	PCDH	GFP
SYN1	PEGFP-N1	FLAG GFP
MUNC18-3	PEGFP-N1	FLAG GFP
PACSIN1	PEGFP-N1	FLAG GFP

SCAMP1	PEGFP-N1	FLAG	GFP
MUNC18-1	PEGFP-N1	FLAG	GFP
PPP3CA	PEGFP-N1	FLAG	GFP
STX17	PEGFP-N1	FLAG	GFP
VAMP7	CMV10	FLAG	
SYT7	PEGFP-N1	FLAG	GFP
SYT11	PEGFP-N1	FLAG	GFP
SNAP25	PEGFP-N1	FLAG	GFP
DYNAMIN1	CMV10	FLAG	YFP
DYNAMIN2	pMYC-C2	FLAG	MYC
MUNC18-1-145Y-A	PEGFP-N1	FLAG	GFP
MUNC18-1-145Y-H	PEGFP-N1	FLAG	GFP
MUNC18-1-145Y-E	PEGFP-N1	FLAG	GFP
MUNC18-1-145Y-F	PEGFP-N1	FLAG	GFP
FLAG-VAMP7-45Y-A	CMV10	FLAG	
FLAG-VAMP7-45Y-C	CMV10	FLAG	
FLAG-DYNAMIN2-125Y-A	pMYC-C2	FLAG	MYC
FLAG-DYNAMIN2-125Y-E	pMYC-C2	FLAG	MYC
FLAG-DYNAMIN2-125Y-F	pMYC-C2	FLAG	MYC
His-DYNAMIN2	pET-28a	His	
His-DYNAMIN2-125Y-E	pET-28a	His	
His-DYNAMIN2-125Y-F	pET-28a	His	
SNAP25-101Y-A	PEGFP-N1	FLAG	GFP
PCDH-MUNC18-1-WT	PCDH	GFP	
PCDH-MUNC18-1-145Y-A	PCDH	GFP	
PCDH-MUNC18-1-145Y-H	PCDH	GFP	
PCDH-MUNC18-1-145Y-E	PCDH	GFP	
PCDH-MUNC18-1-145Y-F	PCDH	GFP	
His-MUNC18-1-WT	Pet15b	His	
His-MUNC18-1-145Y-H	Pet15b	His	
His-MUNC18-1-145Y-E	Pet15b	His	
His-MUNC18-1-145Y-F	Pet15b	His	
SYNTAXIN1	PEGFP-N1	FLAG	GFP
PCDH-DYNAMIN2-WT	PCDH	GFP	
PCDH-DYNAMIN2-125Y-E	PCDH	GFP	
PCDH-DYNAMIN2-125Y-F	PCDH	GFP	

645

Plasmid	Primer sequence
His-PTPMEG2-333Y-A	F:5'GAAACCTAGAGAAAAACCGTGCGGGGGATGTACCCTGCCTGGAC 3' R:5'GTCCAGGCAGGGTACATCCCCGCACGGTTTTTCTCTAGGTTTC 3'

His-PTPMEG2-334G-R	F: 5' CTAGAGAAAAACCGTTATCGTGATGTACCCTGCCTGGAC 3' R: 5' GTCCAGGCAGGGTACATCACGATAACGGTTTTTCTCTAG 3'
His-PTPMEG2-335D-A	F: 5' GAAAAACCGTTATGGGGCGGTACCCTGCCTGGACC 3' R: 5' GGTCCAGGCAGGGTACCGCCCCATAACGGTTTTTC 3'
His-PTPMEG2-471Y-A	F: 5' AGTTCTTGAGCTGGCCAGACGCGGGTGTCCCTTCCTCA 3' R: 5' TGAGGAAGGGACACCCGCGTCTGGCCAGCTCAAGAAGT 3'
His-PTPMEG2-471Y-F	F: 5' GCTGGCCAGACTTTGGTGTCCCTTC 3' R: 5' GAAGGGACACCAAAGTCTGGCCAGC 3'
His-PTPMEG2-519I-A	F: 5' ATTGCAGTGCAGGCGCGGGCAGGACAGGT 3' R: 5' ACCTGTCCTGCCCCGCGCCTGCACTGCAAT 3'
His-PTPMEG2-559Q-A	F: 5' AGAGGGCCTTCAGCATCGCGACCCCTGAGCAGTACTA 3' R: 5' TAGTACTGCTCAGGGGTGCGGATGCTGAAGGCCCTCT 3'
PCDH-PTPMEG2	F: 5' CCATAGAAGATTCTAGAATGGAGCCCCGCGACC 3' R: 5' CGTCGACTGCAGAATTCTTACAGATCCTCTTC 3'
MUNC18-1-GFP-145Y-H	F:5'TTCTCCCCCTATGAGTCCCAGGTGCATTCCCTGGACTCCGCTGACTCT 3' R:5'AGAGTCAGCGGAGTCCAGGGAATGCACCTGGGACTCATAGGGGAGAA 3'
MUNC18-1-GFP-145Y-A	F:5'TCTCCCCCTATGAGTCCCAGGTGGCTTCCCTGGACTCCGCTGACTCTT 3' R:5'AAGAGTCAGCGGAGTCCAGGGAAGCCACCTGGGACTCATAGGGGAGA 3'
GST-MUNC18-1-145Y-H	F:5'TCCAAAATCGGATCTGGTTCCGCGTGGATCCATGGATTACAAGGATGACGACGATA 3' R:5'CGAGGCAGATCGTCAGTCAGTCACGATGCGGCCGCTCACTCCATTGTTGGAGCCTGATCCTCAA 3'
GST-MUNC18-1-145Y-E	F:5'TCTCCCCCTATGAGTCCCAGGTGGAGTCCCTGGACTCCGCTGACTCTTTCC 3' R:5'GTCAGCGGAGTCCAGGGACTCCACCTGGGACTCATAGGGGAGAAACGC 3'
GST-MUNC18-1-145Y-F	F:5'TCTCCCCCTATGAGTCCCAGGTGTTTTCCCTGGACTCCGCTGACTCTTC 3' F:5'GAAAGAGTCAGCGGAGTCCAGGGAAAACACCTGGGACTCATAGGGG 3'
FLAG-VAMP7-45Y-A	F: 5' CTGAAAATAATAAACTAACTGCCTCACATGGCAATTATTTGT 3' R: 5' ACAAATAATTGCCATGTGAGGCAGTTAGTTTATTATTTTCAG 3'
FLAG-VAMP7-45Y-C	F: 5' CTGAAAATAATAAACTAACTTGCTCACATGGCAATTATTTG 3' R: 5' CAAATAATTGCCATGTGAGCAAGTTAGTTTATTATTTTCAG 3'

FLAG-MYC-DYNAMIN2	F:5'TAGCAAGATCTCGAGCTCAAGCTTCGAATTCGATTACAAGGACGACGATGACAAGATGGGCAACCGCGGGATGGAAGAGCTCATC 3' R:5'CGGTGGATCCCCGGGCCCCGCGGTACCGTCGACCTAGTCGAGCAGGGACGGC 3'
FLAG-MYC-DYNAMIN2--125Y-A	F:5'GGTGCTCGAGTGCGGCCGCAAGCTTGTCGACCTAGTCGAGCAGGACGGCTC 3' R:5'GAGGGTCAAGTTCAACACGTGTGGTGAGGCGACCCGAAGGTTGATGGGCACAGG 3'
FLAG-MYC-DYNAMIN2-RFP-125Y-E	F:5'TGCCCATCAACCTTCGGGTCGAGTCACCACACGTGTTGAACTTGAC 3' R:5'CAGCTGCCGGTAATCCTTAGCGACATTCCTCTGCTCAGTGTTGAA 3'
FLAG-MYC-DYNAMIN2-RFP-125Y-F	F:5'TGCCCATCAACCTTCGGGTCCTTCTCACCACACGTGTTGAACTTGAC 3' R:5'TCAAGTTCAACACGTGTGGTGAGAAGACCCGAAGGTTGATGGGCACAGG 3'
His-DYNAMIN2	F:5'CCCTGTGCCATCAACCTTCGGGTCTACTCACCACACGTGTTGAACTTGACC 3' R:5'GGTCAAGTTCAACACGTGTGGTGAGTAGACCCGAAGGTTGATGGGCACAGGG 3'
His-DYNAMIN2-125Y-E	F:5'CAGCGGCCTGGTGCCGCGCGGCAGCCATATGGGCAACCGCGGGATGGAAGAGCTC 3' R:5'GGTGCTCGAGTGCGGCCGCAAGCTTGTCGACCTAGTCGAGCAGGGACGGCT 3'
His-DYNAMIN2-125Y-F	F:5'CAGCGGCCTGGTGCCGCGCGGCAGCCATATGGGCAACCGCGGGATGGAAGAGCTCA 3' R:5'GGTGCTCGAGTGCGGCCGCAAGCTTGTCGACCTAGTCGAGCAGGGACGGCTC 3'
SNAP25-101Y-A	F:5'TCGCCACCATGGATTACAAGGATGACGACGATAAGATGGCCGAGGACGCAGACATGCGTA 3' R:5'TACGCATGTCTGCGTCCTCGGCCATCTTATCGTCGTCATCCTTGTAAATCCATGGTGCGCA 3'

Q-rtPCR Primer sequence

PTP-MEG2	F:5' AGTTTGATGTGCTCCGTGC 3' R:5' AGAGGGCAATGGAGGCTCC 3'
MUNC18-1	F: 5' TGGAAGGTGCTGGTGGTGG A 3' R: 5' GCAGTCGGCGGGTCTTAA 3'
DYNAMIN2	F: 5' TTCGGTGCTCGAGAACTTCG 3' R: 5' CTCTGCTTCGATCTCCTGCC 3'
β -ACTIN	F: 5' AGGGCTATGCTCTCCCTCAC 3' R: 5' CTCTCAGCTGTGGTGGTGAA 3'

Recombinant lentivirus construction and lentivirus infection

For recombinant lentivirus packaging, the construction and infection was carried out as previously reported (Zhang et al., 2018). Plasmids carrying different genes including pCDH-PTP-MEG2-G³³⁴R/D³³⁵A/Y⁴⁷¹A/Y⁴⁷¹F/I⁵¹⁹A/Q⁵⁵⁹A/R⁴⁰⁹A/R⁴¹⁰A/WT-GFP, pCDH-MUNC18-1-Y¹⁴⁵H/Y¹⁴⁵E/Y¹⁴⁵F/WT-GFP and pCDH-DYNAMIN2-Y¹²⁵E/Y¹²⁵F/WT-GFP were transfected into 293T cells using Lipofectamine TM 2000 (Thermo Fisher, Waltham, MA, USA) according to the manufacturer's instructions. Three days after transfection, the supernatant of virus encoding PTP-MEG2, MUNC18-1 or DYNAMIN2 were collected and filtered. The PTP-MEG2, MUNC18-1 or DYNAMIN2 lentivirus (1×10⁶ TU/ml) was used to infect the primary chromaffin cells in later experiments.

ELISA

Freshly isolated adrenal medullas from adult female mice (6–8 weeks) were cultured in DMEM medium containing 1% penicillin/streptomycin and 10% FBS. After 2 hours starvation, adrenal medullas were stimulated with high KCl (70mM), AngII (100nM) for 1 min, with or without pre-incubation of a specific PTP-MEG2 inhibitor (400nM) for 1 hours. The supernatants were collected, and the epinephrine or norepinephrine secretion were determined by using the Epinephrine or norepinephrine ELISA kit (Shanghai Jianglai Co.,Ltd, JL11194-48T/JL13969-96T) according to the manufacture's protocol.

Quantitative real-time PCR

Adrenal medullas were freshly isolated from adult female mice (6–8 weeks). The lentivirus encoding wild type or mutants of PTP-MEG2, MUNC18-1 or DYNAMIN2 (1×10⁶ TU/ml) were used to infect the primary chromaffin cells. On the third day, about 10 to 20 pheochromaffin cells with the different brightness were selected in each plate under the fluorescence microscope and the fluorescence photos were taken. After classification by different brightness, the cells were glued with the tips of ultra-fine glass tubes, and the tips of glass tubes with the cells were directly broken in the PCR tube. The PCR tube was preloaded with 5ul RNA enzyme inhibitors (Invitrogen, 10777019). 1ul DNA scavenger was added to the

PCR tube, which was left at room temperature for half an hour and then terminated with a terminator. The purpose of this step is to remove the interference of genomic DNA. All the samples were reverse-transcribed using the Revertra Ace qPCR RT Kit (TOYOBO FSQ-101) to obtain cDNA. Then the quantitative real-time PCR was performed with the LightCycler apparatus (Bio-Rad) using the FastStart Universal SYBR Green Master (Roche). The expression of actin was used as a control.

Electrochemical amperometry

5-mm glass carbon fiber electrode (CFE) was used to measure quantal CA released from the mouse adrenal medulla chromaffin cell as previously described (Liu et al., 2017). We used a Multiclamp 700B amplifier (2012, Axon, Molecular Devices, USA) to perform electrochemical amperometry, which interfaced to Digidata 1440A with the pClamp 10.2 software (Liu et al., 2017). The holding potential of 780 mV was used to record the amperometric current (I_{amp}). All experiments were performed at room temperature (20–25°C). The CFE surface was positioned in contact with the membrane of clean primary chromaffin cells to monitor the quantal release of the hormone containing catecholamine substances. In our kinetic analysis of single amperometric spike, we only used the amperometric spikes with $S/N > 3$ (signal/noise). The standard external solution for our amperometry measurement is as follows: 5 mM KCl, 10 mM glucose, 10 mM HEPES pH 7.4, 2 mM $CaCl_2$, 150 mM NaCl and 2 mM $MgCl_2$. We analyzed all data using Igor (WaveMetrix, Lake Oswego, Oregon) and a custom-made macro program. Statistical data were given as the mean $\pm$ SEM and analyzed with one-way ANOVA.

Electron microscopy

The female mice (6–8 weeks) were decapitated, and the adrenal medullas were freshly isolated and cut to 150- μ m-thick sections. The sections were immersed in Ringer's saline (125mM NaCl, 2.5mM KCl, 1.25mM NaH_2PO_4 , 26mM $NaHCO_3$, 10mM D-Glucose, 2mM $CaCl_2$, 1mM $MgCl_2$) for 40 minutes at room temperature. During this period, continuous gases of 5% CO_2 and 95% O_2 were offered to the saline to ensure the survival of the tissue slice. After 40 minutes of starvation, the sections were stimulated with different conditions (control; only 100nM Ang II agonists for 1 min; only 400nM PTP-MEG2 inhibitor for 45 min; 100nM AngII agonists and

400nM PTP-MEG2 inhibitor for 1 min or 45 min) at 37°C respectively. These sections were firstly immersed in precooled 3% glutaraldehyde and fixed at 4°C for 2 hours, and then rinsed in PBS isotonic buffer, with repeated liquid exchanges and cleaning overnight, so that the samples were thoroughly rinsed and soaked in the buffer. After rinsing, the sample was fixed at 4°C with 1% osmium acid for 2 hours. It was rinsed with isosmotic buffer solution at 0.1M PBS for 15 minutes. The sections were dehydrated with ethanol at concentrations of 50%, 70%, 90%, then ethanol at concentration of 90% and acetone at concentration of 90%, at last only acetone at concentrations of 90%, 100%. We then replaced the acetone with the Epon gradually. The sections were added to Epon and polymerized at 60°C for 36 hours. Ultra-thin sections were performed at the thickness of 60nm by the LKB-1 ultra microtome, and then the ultra-thin sections were collected with the single-hole copper ring attached with formvar film. The sample was stained with 2% uranium acetate for 30 minutes, and then stained with 0.5% lead citrate for 15 minutes. These prepared samples were examined by JEM-1200EX electron microscope (Japan).

Western

Cells or medulla sections were lysed in lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM NaF, 1% NP-40, 2mM EDTA, Tris-HCl pH 8.0, 10% glycerol, 0.25% sodium deoxycholate, 1mM Na₃VO₄, 0.3μM aprotinin, 130μM bestatin, 1μM leupeptin, 1μM repstatin and 0.5% IAA) after rinsing with the pre-chilled PBS on ice. Cell and tissue lysates were kept on ice for 35 min and then sediment via centrifugation for 15 min at 4 °C. The whole-cell and tissue protein lysates samples (30μg) were prepared for SDS-PAGE. The proteins in the gel were transferred to a nitrocellulose filter membrane by electro blotting, then probed with the appropriate primary and secondary antibodies. Antibody binding was detected by an HRP system.

Immunofluorescence.

For the acquisition of tissue cells used in immunofluorescence, the mice were decapitated, and the adrenal medullas were freshly isolated (female mice, 6–8 weeks).The isolated adrenal medullas was immersed in 4% paraformaldehyde for fixation overnight at 4°C. Then the fixed tissues were washed for 4 hours in PBS containing 10% sucrose at 4°C for 8 hours in 20%

sucrose, and in 30% sucrose overnight. Then these adrenal medullas were imbedded in Tissue-Tek OCT compound and then mounted and frozen them at -25°C. Subsequently, the adrenal medulla was cut to 4-μm-thick coronal serial sections. The adrenal medullas sections were blocked with 1% (vol/vol) donkey serum, 2.5% (wt/vol) BSA and 0.1% (vol/vol) Triton X-100 in PBS for 1.5 h. Then, the slides were incubated with primary antibodies against PTP-MEG2 (1:100), NSF (1:50), MUNC18-1 (1:50), VAMP7 (1:50), DYNAMIN2 (1:100), SNAP25 (1:100), PACSIN1 (1:50) at 4°C overnight. After washing with PBS for 3 times, the slides were incubated with the secondary antibody (1:500) for 1 h at room temperature. The slides were stained with DAPI (1:2000). Images were captured using a confocal microscope (ZEISS, LSM780). The Pearson's co-localization coefficients were analyzed with Image-Pro Plus.

K_m and k_{cat} measurements.

Enzymatic activity measurement was carried out as previously reported (Li et al., 2016; Wang et al., 2014). The standard solution (DMG buffer) for our enzymatic reactions is following: 50 mM 3, 3-dimethyl glutarate pH 7.0, 1 mM EDTA, 1 mM DTT. The ionic strength was maintained at 0.15 M (adjusted by NaCl). For the pNPP activity measurement, 100 μl reaction mixtures were set up in a total volume in a 96-well polystyrene plate (Thermo Fisher Scientific, Waltham, MA, US). The substrate concentration ranging from 0.2 to 5 K_m was used to determine the k_{cat} and K_m values. Reactions were started by the addition of an appropriate amount of His-PTP-MEG2-CD-WT or corresponding mutants, such as Y³³³A, G³³⁴R, D³³⁵A, Y⁴⁷¹A, Y⁴⁷¹F, I⁵¹⁹A, Q559A, R⁴⁰⁹A, and R⁴¹⁰A. The dephosphorylation of pNPP was terminated by adding 120 μl 1M NaOH, and the enzymatic activity was monitored by measuring the absorbance at 405 nm. The activities toward phospho-peptide segment derived from NSF or MUNC18-1 were measured as following: In the first column, 90 μl diluted NSF/MUNC18-1/DYNAMIN2 phospho-peptide substrate (100 μM) was added. The successive columns were diluted by 1.5 times. The phospho-peptide substrates were preincubated at 37°C for 5 min. Reactions were started by the addition of an appropriate amount of enzymes. The dephosphorylation of NSF/MUNC18-1/DYNAMIN2 was terminated by adding 120 μl Biomol green, and the enzymatic activities were monitored by measuring the absorbance at 620 nm. The steady-state kinetic parameters were determined from a direct fit of the data to the

Michaelis-Menten equation using GraphPad Prism 5.0.

GST-pull down

To screen the candidate proteins interacting with PTP-MEG2, the GST beads were washed five times by cold binding buffer (20mM HEPES pH7.5, 1mM DTT, 1mM EDTA, and 100mM NaCl) and incubated with 5µg purified GST-PTP-MEG2-CD-D⁴⁷⁰A protein for 2 hours at 4°C. PC12 cells were transfected with FLAG-SYN1-GFP, FLAG-MUNC18-1-GFP, FLAG-MUNC18-1-Y¹⁴⁵A-GFP, FLAG-MUNC18-1-Y¹⁴⁵H-GFP, FLAG-MUNC18-1-Y¹⁴⁵E-GFP, FLAG-MUNC18-1-Y¹⁴⁵F-GFP, FLAG-MUNC18-3-GFP, FLAG-PACSIN1-GFP, FLAG-SCAMP1-GFP, FLAG-PPP3CA-GFP, FLAG-STX17-GFP, FLAG-VAMP7, FLAG-VAMP7-Y⁴⁵A, FLAG-VAMP7-Y⁴⁵C, FLAG-SYT7-GFP, FLAG-SYT11-GFP, FLAG-SNAP25-GFP, FLAG-SNAP25-Y¹⁰¹A-GFP, FLAG-DYNAMIN1-GFP, FLAG-DYNAMIN2, FLAG-DYNAMIN2-Y¹²⁵A, FLAG-DYNAMIN2-Y¹²⁵E, FLAG-DYNAMIN2-Y¹²⁵F. After stimulation with 100nM AngII for 5 minutes at 37 °C, the cells were washed and then lysed in lysis buffer [20 mM HEPES pH 7.5, 100 mM NaCl, 0.5% NP-40, 5 mM iodoacetic acid, and a protease inhibitor mixture (final concentrations, 10µg of leupeptin, 1µg of aprotinin, 1µg of pepstatin, 1µg of antipain, and 20µg of phenylmethylsulfonyl fluoride per ml), 10mM DTT, 2mM EDTA] on ice for 30 minutes, then centrifuged at 12000rpm for 15 minutes at 4 °C. 20µl GST beads-PTP-MEG2-D⁴⁷⁰A protein was added into 500µl supernatants and the mixtures were subjected to end-to-end rotation at 4 °C for 2 hours. The GST beads and their binding proteins were washed five times with cold binding buffer to exclude the unspecific binding proteins. The pull-down experiment of MUNC18-1 and SYNTAXIN1 were described similar to above description. The GST beads were washed five times by cold binding buffer (described as above). After that, 5µg purified GST-MUNC18-1-WT or its Y¹⁴⁵H, Y¹⁴⁵E or Y¹⁴⁵F mutant proteins were added into 20µl GST-agarose and incubated at for 4 °C 2 hours with end to end rotation. PC12 cells transfected with FLAG-SYNTAXIN1 were lysed in lysis buffer (described as above) and centrifuged to remove the pallets. The supernatants were added with 20µl GST beads/GST-fusion protein and the mixtures were subjected to end-to-end rotation at 4 °C for 2 hours. The FLAG-SYNTAXIN1 was detected with FLAG antibody.

GFP-pull down

PC12 cells were infected with lentiviruses encoding GFP-tagged PTP-MEG2-D⁴⁷⁰A of wild type and different mutant types. After stimulation with 100nM AngII for 5 minutes at 37 °C, the cells were washed and then lysed in lysis buffer [20 mM HEPES pH 7.5, 100 mM NaCl, 0.5% NP-40, 5 mM iodoacetic acid, and a protease inhibitor mixture (final concentrations, 10µg of leupeptin, 1µg of aprotinin, 1µg of pepstatin, 1µg of antipain, and 20µg of phenylmethylsulfonyl fluoride per ml), 10mM DTT, 2mM EDTA] on ice for 30 minutes, then centrifuged at 12000rpm for 15 minutes at 4 °C. The GFP beads were washed five times by cold binding buffer (20mM HEPES pH7.5, 1mM DTT, 1mM EDTA, and 100mM NaCl). 25µl anti-GFP-antibody conjugated beads were added into 500µl supernatants and the mixtures were subjected to end-to-end rotation at 4 °C for 1 hours. The PTP-MEG2-D⁴⁷⁰A-GFP proteins were pulled down and washed five times with cold binding buffer to exclude the unspecific binding proteins. The associated PTP-MEG2 substrates in the GFP-pull-down beads were then examined by western blot.

Immunoprecipitation and in vitro dephosphorylation

Rat adrenal medullas were isolated and cut into pieces in D-hanks buffer and stimulated with 70mM KCl or 100nM AngII for 5 minutes. The tissues were then lysed and grinded on ice in lysis buffer supplemented with proteinase inhibitor as described before. The lysates were centrifuged at 12000 rpm for 20 minutes at 4 °C and the pellets were removed. Before incubation with the lysates in the later step, the 1µg primary antibodies of NSF, MUNC18-1, VAMP7, SNAP25 or DYNAMIN2 were incubated with 20µl Protein A/G beads by end-to-end rotation overnight at 4 °C. Then the supernatants were incubated with primary antibody pre-coated with Protein A/G beads and rotated for 2 hours. 5µg purified PTP-MEG2-WT protein or control solution were added into the lysates for the in vitro dephosphorylation. A pan-phospho-tyrosine antibody pY²⁰/pY⁹⁹ was used in Western blotting to detect the phosphorylated tyrosine of NSF/MUNC18-1/VAMP7/SNAP25/DYNAMIN2 in adrenal medullar with or without incubation with the PTP-MEG2.

Protein Expression and Purification

The wide type and mutant proteins of His-tagged PTP-MEG2-catalytic domain were expressed in BL21-DE3 Escherichia coli as previously described (Pan et al., 2013). In brief, 0.4 mM isopropyl 1-thio-D-galactopyranoside (IPTG) was used to induce the expression of His-PTP-MEG2, and the bacteria lysates were centrifuged at 12000 rpm for 1 hour. Ni-NTA Agarose was applied to bind the His-tagged PTP-MEG2 and an imidazole gradation was used to elute the binding proteins. His-PTP-MEG2 was then purified with gel filtration chromatography to achieve at least 95% purity. The wide type and mutant proteins of GST-PTP-MEG2 and GST-MUNC18-1 were also expression in E.coli in presence of 0.4 mM IPTG for 16 hours at 25°C. After centrifugation and lysis, the proteins were purified by binding with GST-Sepharose for 2 hours and eluted by GSH.

Crystallization and Data Collection

For crystallization, His-PTP-MEG2-C⁵¹⁵A/D⁴⁷⁰A protein (concentration at 15mg/ml) was mixed with NSF-pY⁸³ peptide (EVSLpYTFDK) or MUNC18-1-pY¹⁴⁵ peptide (ESQVpYSLDS) with molar ratio as 1:3 in buffer A (pH 7.2, 20 mM HEPES, 350 mM NaCl, and 1 mM DTT). 1μl mixed protein was blended with 1μl buffer B (pH 6.4, 20% PEG 4000, 0.2M KSCN, 10% ethylene glycol, 0.1M bis-tris propane) at 4°C for 3 days before crystals appears. The cubic crystals were preserved in liquid nitrogen very quickly dipped in storage buffer (buffer B supplemented with 10% glycerol). The data were collected at Shanghai Synchrotron Radiation Facility beamline BL17U1 using 0.98Å X-ray wavelength and analyzed by HKL2000.

Structural determination and refinement

The crystals of PTP-MEG2-NSF-pY⁸³ and PTP-MEG2-MUNC18-1-pY¹⁴⁵ peptides belong to the P2₁2₁2 space group. In each asymmetric unit, both PTPMEG2-NSF-pY⁸³ and PTPMEG2-MUNC18-1-pY¹⁴⁵ contain one monomer in one unit. Molecular replacement with Phaser in the CCP4 software package, with PTP-MEG2 catalytic domain (PDB code: 2PA5, water deleted) as the initial search model. Further refinements were carried out using the PHENIX program with iterative manual building in COOT. The data of the final refined structures are shown in Supplementary information Table 1.

BRET assay

The BRET experiment was performed to monitor the mutation effects of DYNAMIN2 on AT1aR endocytosis in response to AngII (1 μ M) stimulation as previously described (Liu et al., 2017). Plasmids encoding DYNAMIN2 (DYNAMIN2-WT, DYNAMIN2-Y¹²⁵E or DYNAMIN2-Y¹²⁵F) and LYN-YFP, AT1aR-C-RLUC were co-transferred into HEK293 cells at 1:1:1 ratio for 48 h. After 12 h of starvation, cells were digested with trypsin and harvested. Then the transfected cells were washed with PBS at least three times and evenly distributed into a 96-well plate (Corning Costar Cat. # 3912). Cells were stimulated with AngII (1 μ M) for 25 min at 37 °C. Afterwards, Coelenterazine h was incubated with the cells at 25 °C (Promega S2011, final concentration, 5 μ M). We used two different light emissions for BRET measurements (530/20 nm for yellow fluorescent protein and 480/20 nm for luciferase).

GTPase activity of DYNAMIN2

To prepare His-tagged DYNAMIN2-WT, DYNAMIN2-Y¹²⁵E, DYNAMIN2-Y¹²⁵F (His-DYNAMIN2-WT, His-DYNAMIN2-Y¹²⁵E, His-DYNAMIN2-Y¹²⁵F), DNA fragments were generated by PCR using MYC-DYNAMIN2 as the template and subcloned into pET-28a (+) plasmid. The resulting plasmids were transformed into bacterial BL21-DE3-RIPL cells for protein expression. The DYNAMIN proteins were then purified by affinity chromatography. We measured the DYNAMIN2 GTPase activity by using GTPase-Glo assay test kit (V7681) from Promega Corporation according to its instructions.

Bioinformatic search of PTP-protein interactions

We identified the PTP-protein interactions by two independent bioinformatic analyses. On one site, we extracted the potential PTP-interacting proteins from the STRING database (Szklarczyk et al., 2015) by setting the parameters of Homo sapiens. On the other site, we used Pubtator (Wei et al., 2013) to text-mine potential PTP-protein associations from PubMed literature (by 2018.9) via the search of combinational keywords such as “tyrosine phosphorylation mutation, vesicular, fusion, and human”. We compared these two protein lists to produce a consensus PTP-interacting protein list. Subsequently, we narrowed down the protein list by satisfying following constraints: (a) The protein should express in the adrenal

gland as documented in the TissueAtlas (Thul et al., 2017); (b) The protein should expose tyrosine residue(s) on surface for phosphorylation as simulated by the Molecular Operating Environment (MOE) (Vilar et al., 2008); (c) On the protein, at least one predicted tyrosine phosphorylation site predicted by the PhosphoSitePlus (Hornbeck et al., 2015) is also experiment-validated. The refined PTP-protein pairs were then ready for later experimental analyses.

LC-MS/MS analysis

Rat adrenal medullas were isolated and cut into pieces in D-hanks buffer and stimulated with 100nM AngII for 5 minutes. The tissues were then lysed and grinded on ice in lysis buffer supplemented with protease inhibitors. The lysates were centrifuged at 12000 rpm for 20 minutes at 4 °C and the pellets were removed. Before incubation with the lysates in the later step, the GST beads were washed five times by cold binding buffer (20mM HEPES pH7.5, 1mM DTT, 1mM EDTA, and 100mM NaCl) and incubated with 5µg purified GST-PTP-MEG2-CD-D⁴⁷⁰A protein for 2 hours at 4°C. 20µl GST beads-PTP-MEG2-D⁴⁷⁰A protein was added into 500µl supernatants and the mixtures were subjected to end-to-end rotation at 4 °C for 2 hours. The GST beads and their binding proteins were washed five times with cold binding buffer to exclude the unspecific binding proteins. Denatured proteins were separated by 10% SDS-PAGE and subjected to trypsin digestion. Phosphopeptides were analyzed by the LTQ Orbitrap Elite (Thermo Scientific, Beijing Qinglian Biotech Co., Ltd). Spectra were analyzed by Proteome Discoverer software, and phosphorylation sites were confirmed manually.

Protein degradation assay

HEK293 cell were seeded in 6-well plates. Plasmids encoding MUNC18-1 (MUNC18-1-WT, MUNC18-1-Y¹⁴⁵E or MUNC18-1-Y¹⁴⁵F) or DYNAMIN2 (DYNAMIN2-WT, DYNAMIN2-Y¹²⁵E or DYNAMIN2-Y¹²⁵F) was transferred into HEK293 cells for 24 h. Cells were treated with cycloheximide (CHX 10µg/ml) and harvested at different time points (0, 4, 8, 12h) for western blot analysis.

Statistical analysis

All data are presented as mean $\pm$ SEM. All data were analyzed using two-tailed Student's t-test or one-way ANOVA. All of the Western films were scanned, and band intensity was quantified with ImageJ software (National Institutes of Health, Bethesda MD). $P < 0.05$ was considered as statistically significant.

DATA AVAILABILITY

The coordinates and density map for the PTP-MEG2-NSF-pY⁸³ (PDB ID: 6KZQ) and PTP-MEG2-MUNC18-1-pY¹⁴⁵ (PDB ID: 6L03) peptides has been deposited in protein data bank. All other data are available upon request to the corresponding authors.

ACKNOWLEDGEMENTS

We thank Dr Michael Xi Zhu for stimulating discussions and critical reading of the manuscript. We thank Yanmei Lu from Shandong jiaotong hospital, for her help with Transmission electron microscopy analysis. We thank Daolai Zhang and Mingliang Ma for their technical assistance in lentivirus packaging. We thank Yujing Sun and Zhixin Liu for their technical assistance in electrochemical recording. We acknowledge support from the National Key Basic Research Program of China Grant 2018YFC1003600 (to X.Y. and J.-P.S.), the National Natural Science Foundation of China Grant 81773704 (to J.-P.S.) and Grant 81601668 (to Y.-F.X.), the National Science Fund for Distinguished Young Scholars Grant 81825022 (to J.-P.S.), the National Science Fund for Excellent Young Scholars Grant 81822008 (to X. Y.) and the Rolling program of ChangJiang Scholars and Innovative Research Team in University Grant IRT_17R68 (to Y. S.). S.Z. and Z.-Y. Z. are supported by NIH RO1 CA69202.

AUTHOR CONTRIBUTIONS:

J.-P.S. and X.Y. conceived the whole research and initiated the project. J.-P.S., X.Y., Y.-F.X. and X.C. designed all the experiments. J.-P.S. and X.Y. supervised the overall project design and execution. X.C., Y.-F.X., Z.Y., X.Y. and J.-P.S. participated in data analysis and interpretation. C.-H.L. and Y.-J.W. performed electrochemical experiments. Z.Y., P.X., Z.-L.Z. helped us collect crystal data and analyze crystal structure. M.C., K.-S.L., Y.-C.S. performed cell biology, molecular biology and biochemistry experiments. Z.-G.X. provided DYNAMIN2

plasmid. Z.-Y.Z. and S.Z. synthesized and purified Compound 7 (PTP-MEG2 inhibitor). X.-Z.Y. and Z.-L.J. performed substrate bioinformatics screening. Z.-Y.Z., W.-D.Z., C.-H.W. and C.W. provided insightful idea and experimental designs. J.-P.S, Y.-F.X., X.C. and X.Y. wrote the manuscript. All of the authors have seen and commented on the manuscript.

ADDITIONAL INFORMATION

Competing financial interests The authors declare no competing financial interests.

ABBREVIATIONS

PTP: protein tyrosine phosphatase, NSF: N-ethylmaleimide-sensitive fusion protein, AngII: Angiotensin II, EPI: epinephrine, NE: norepinephrine, CFE: carbon fiber electrode, LDCVs: large-dense-core vesicles, PSF: pre-spike foot, SAF: stand-alone foot, pNPP: p-nitrophenyl phosphate, MUNC18: Mammalian homolog of Unc-18, Cav1.2: Voltage-gated calcium channel subunit alpha Cav1.2, VAMP7: Vesicle-associated membrane protein 7, PPP3CA: Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform, PM: plasma membrane, LYP: Lymphoid phosphatase, SKAP-HOM: Src kinase-associated phosphoprotein, HER2: Receptor tyrosine-protein kinase erbB-2, SHP1: Protein-tyrosine phosphatase SHP-1, PTPH1: Protein-tyrosine phosphatase H1.

REFERENCE

- Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., and Mustelin, T. (2004). Protein tyrosine phosphatases in the human genome. *Cell* 117, 699-711.
- Alvarez de Toledo, G., Fernandez-Chacon, R., and Fernandez, J.M. (1993). Release of secretory products during transient vesicle fusion. *Nature* 363, 554-558.
- Baker, R.W., and Hughson, F.M. (2016). Chaperoning SNARE assembly and disassembly. *Nat Rev Mol Cell Biol* 17, 465-479.
- Ballif, B.A., Carey, G.R., Sunyaev, S.R., and Gygi, S.P. (2008). Large-scale identification and evolution indexing of tyrosine phosphorylation sites from murine brain. *Journal of proteome research* 7, 311-318.
- Barr, A.J., Ugochukwu, E., Lee, W.H., King, O.N., Filippakopoulos, P., Alfano, I., Savitsky, P., Burgess-Brown, N.A., Muller, S., and Knapp, S. (2009). Large-scale structural analysis of the classical human protein tyrosine phosphatome. *Cell* 136, 352-363.
- Chai, Y.J., Sieracki, E., Tomatis, V.M., Gormal, R.S., Giles, N., Morrow, I.C., Xia, D., Gotz, J., Parton, R.G., Collins, B.M., *et al.* (2016). Munc18-1 is a molecular chaperone for alpha-synuclein, controlling its self-

replicating aggregation. *J Cell Biol* 214, 705-718.

Chen, X.K., Wang, L.C., Zhou, Y., Cai, Q., Prakriya, M., Duan, K.L., Sheng, Z.H., Lingle, C., and Zhou, Z. (2005). Activation of GPCRs modulates quantal size in chromaffin cells through G(betagamma) and PKC. *Nat Neurosci* 8, 1160-1168.

Cho, C.Y., Koo, S.H., Wang, Y., Callaway, S., Hedrick, S., Mak, P.A., Orth, A.P., Peters, E.C., Saez, E., Montminy, M., *et al.* (2006). Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. *Cell Metab* 3, 367-378.

Cijsouw, T., Weber, J.P., Broeke, J.H., Broek, J.A., Schut, D., Kroon, T., Saarloos, I., Verhage, M., and Toonen, R.F. (2014). Munc18-1 redistributes in nerve terminals in an activity- and PKC-dependent manner. *J Cell Biol* 204, 759-775.

Dittman, J.S., and Ryan, T.A. (2019). The control of release probability at nerve terminals. *Nat Rev Neurosci* 20, 177-186.

Doody, K.M., and Bottini, N. (2014). "PEST control": regulation of molecular barcodes by tyrosine phosphatases. *Cell Res* 24, 1027-1028.

Eitzen, G. (2003). Actin remodeling to facilitate membrane fusion. *Biochimica et biophysica acta* 1641, 175-181.

Fisher, R.J., Pevsner, J., and Burgoyne, R.D. (2001). Control of fusion pore dynamics during exocytosis by Munc18. *Science* 291, 875-878.

Gabel, M., Delavoie, F., Royer, C., Tahouly, T., Gasman, S., Bader, M.F., Vitale, N., and Chasserot-Golaz, S. (2019). Phosphorylation cycling of Annexin A2 Tyr23 is critical for calcium-regulated exocytosis in neuroendocrine cells. *Biochimica et biophysica acta Molecular cell research* 1866, 1207-1217.

Gaisano, H.Y. (2017). Recent new insights into the role of SNARE and associated proteins in insulin granule exocytosis. *Diabetes Obes Metab* 19 Suppl 1, 115-123.

Gu, M., Warshawsky, I., and Majerus, P.W. (1992). Cloning and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to retinaldehyde-binding protein and yeast SEC14p. *Proc Natl Acad Sci U S A* 89, 2980-2984.

Gulyas-Kovacs, A., de Wit, H., Milosevic, I., Kochubey, O., Toonen, R., Klingauf, J., Verhage, M., and Sorensen, J.B. (2007). Munc18-1: sequential interactions with the fusion machinery stimulate vesicle docking and priming. *J Neurosci* 27, 8676-8686.

Harada, K., Matsuoka, H., Miyata, H., Matsui, M., and Inoue, M. (2015). Identification of muscarinic receptor subtypes involved in catecholamine secretion in adrenal medullary chromaffin cells by genetic deletion. *Br J Pharmacol* 172, 1348-1359.

He, E., Wierda, K., van Westen, R., Broeke, J.H., Toonen, R.F., Cornelisse, L.N., and Verhage, M. (2017). Munc13-1 and Munc18-1 together prevent NSF-dependent de-priming of synaptic vesicles. *Nat Commun* 8, 15915.

Hernandez, J.M., Stein, A., Behrmann, E., Riedel, D., Cypionka, A., Farsi, Z., Walla, P.J., Raunser, S., and Jahn, R. (2012). Membrane fusion intermediates via directional and full assembly of the SNARE complex. *Science* 336, 1581-1584.

Hong, W., and Lev, S. (2014). Tethering the assembly of SNARE complexes. *Trends Cell Biol* 24, 35-43.

Hornbeck, P.V., Zhang, B., Murray, B., Kornhauser, J.M., Latham, V., and Skrzypek, E. (2015). PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. *Nucleic Acids Res* 43, D512-520.

Hu, S.H., Christie, M.P., Saez, N.J., Latham, C.F., Jarrott, R., Lua, L.H., Collins, B.M., and Martin, J.L. (2011). Possible roles for Munc18-1 domain 3a and Syntaxin1 N-peptide and C-terminal anchor in SNARE complex formation. *Proc Natl Acad Sci U S A* 108, 1040-1045.

1030 Huynh, H., Bottini, N., Williams, S., Cherepanov, V., Musumeci, L., Saito, K., Bruckner, S., Vachon, E.,
1031 Wang, X., Kruger, J., *et al.* (2004). Control of vesicle fusion by a tyrosine phosphatase. *Nat Cell Biol* 6,
1032 831-839.

1033 Jewell, J.L., Oh, E., Ramalingam, L., Kalwat, M.A., Tagliabracci, V.S., Tackett, L., Elmendorf, J.S., and
1034 Thurmond, D.C. (2011). Munc18c phosphorylation by the insulin receptor links cell signaling directly to
1035 SNARE exocytosis. *The Journal of cell biology* 193, 185-199.

1036 Jones, D.M., Alvarez, L.A., Nolan, R., Ferriz, M., Sainz Urruela, R., Massana-Munoz, X., Novak-Kotzer, H.,
1037 Dustin, M.L., and Padilla-Parra, S. (2017). Dynamin-2 Stabilizes the HIV-1 Fusion Pore with a Low
1038 Oligomeric State. *Cell reports* 18, 443-453.

1039 Kar, U.P., Dey, H., and Rahaman, A. (2017). Regulation of dynamin family proteins by post-translational
1040 modifications. *Journal of biosciences* 42, 333-344.

1041 Korteweg, N., Maia, A.S., Thompson, B., Roubos, E.W., Burbach, J.P., and Verhage, M. (2005). The role
1042 of Munc18-1 in docking and exocytosis of peptide hormone vesicles in the anterior pituitary. *Biol Cell*
1043 97, 445-455.

1044 Laidlaw, K.M.E., Livingstone, R., Al-Tobi, M., Bryant, N.J., and Gould, G.W. (2017). SNARE
1045 phosphorylation: a control mechanism for insulin-stimulated glucose transport and other regulated
1046 exocytic events. *Biochem Soc Trans* 45, 1271-1277.

1047 Li, H., Yang, F., Liu, C., Xiao, P., Xu, Y., Liang, Z., Liu, C., Wang, H., Wang, W., Zheng, W., *et al.* (2016).
1048 Crystal Structure and Substrate Specificity of PTPN12. *Cell Rep* 15, 1345-1358.

1049 Lim, S.H., Moon, J., Lee, M., and Lee, J.R. (2013). PTPRT regulates the interaction of Syntaxin-binding
1050 protein 1 with Syntaxin 1 through dephosphorylation of specific tyrosine residue. *Biochemical and*
1051 *biophysical research communications* 439, 40-46.

1052 Liu, C.H., Gong, Z., Liang, Z.L., Liu, Z.X., Yang, F., Sun, Y.J., Ma, M.L., Wang, Y.J., Ji, C.R., Wang, Y.H., *et al.*
1053 (2017). Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling.
1054 *Nature communications* 8, 14335.

1055 Ma, C., Su, L., Seven, A.B., Xu, Y., and Rizo, J. (2013). Reconstitution of the vital functions of Munc18 and
1056 Munc13 in neurotransmitter release. *Science* 339, 421-425.

1057 Ma, L., Rebane, A.A., Yang, G., Xi, Z., Kang, Y., Gao, Y., and Zhang, Y. (2015). Munc18-1-regulated stage-
1058 wise SNARE assembly underlying synaptic exocytosis. *Elife* 4.

1059 Magadmi, R., Meszaros, J., Damanhour, Z.A., and Seward, E.P. (2019). Secretion of Mast Cell
1060 Inflammatory Mediators Is Enhanced by CADM1-Dependent Adhesion to Sensory Neurons. *Front Cell*
1061 *Neurosci* 13, 262.

1062 Mallozzi, C., D'Amore, C., Camerini, S., Macchia, G., Crescenzi, M., Petrucci, T.C., and Di Stasi, A.M. (2013).
1063 Phosphorylation and nitration of tyrosine residues affect functional properties of Synaptophysin and
1064 Dynamin I, two proteins involved in exo-endocytosis of synaptic vesicles. *Biochimica et biophysica acta*
1065 1833, 110-121.

1066 Mattila, J.P., Shnyrova, A.V., Sundborger, A.C., Hortelano, E.R., Fuhrmans, M., Neumann, S., Muller, M.,
1067 Hinshaw, J.E., Schmid, S.L., and Frolov, V.A. (2015). A hemi-fission intermediate links two mechanistically
1068 distinct stages of membrane fission. *Nature* 524, 109-113.

1069 Meijer, M., Dorr, B., Lammertse, H.C., Blithikioti, C., van Weering, J.R., Toonen, R.F., Sollner, T.H., and
1070 Verhage, M. (2018). Tyrosine phosphorylation of Munc18-1 inhibits synaptic transmission by preventing
1071 SNARE assembly. *EMBO J* 37, 300-320.

1072 Neher, E., and Brose, N. (2018). Dynamically Primed Synaptic Vesicle States: Key to Understand Synaptic
1073 Short-Term Plasticity. *Neuron* 100, 1283-1291.

1074 Oakie, A., and Wang, R. (2018). beta-Cell Receptor Tyrosine Kinases in Controlling Insulin Secretion and
1075 Exocytotic Machinery: c-Kit and Insulin Receptor. *Endocrinology* **159**, 3813-3821.

1076 Ortsater, H., Grankvist, N., Honkanen, R.E., and Sjoholm, A. (2014). Protein phosphatases in pancreatic
1077 islets. *The Journal of endocrinology* **221**, R121-144.

1078 Pan, C., Liu, H.D., Gong, Z., Yu, X., Hou, X.B., Xie, D.D., Zhu, X.B., Li, H.W., Tang, J.Y., Xu, Y.F., *et al.* (2013).
1079 Cadmium is a potent inhibitor of PPM phosphatases and targets the M1 binding site. *Scientific reports*
1080 **3**, 2333.

1081 Seino, S., Takahashi, H., Fujimoto, W., and Shibasaki, T. (2009). Roles of cAMP signalling in insulin granule
1082 exocytosis. *Diabetes Obes Metab* **11 Suppl 4**, 180-188.

1083 Shin, W., Ge, L., Arpino, G., Villarreal, S.A., Hamid, E., Liu, H., Zhao, W.D., Wen, P.J., Chiang, H.C., and Wu,
1084 L.G. (2018). Visualization of Membrane Pore in Live Cells Reveals a Dynamic-Pore Theory Governing
1085 Fusion and Endocytosis. *Cell* **173**, 934-945 e912.

1086 Sitarska, E., Xu, J., Park, S., Liu, X., Quade, B., Stepien, K., Sugita, K., Brautigam, C.A., Sugita, S., and Rizo,
1087 J. (2017). Autoinhibition of Munc18-1 modulates synaptobrevin binding and helps to enable Munc13-
1088 dependent regulation of membrane fusion. *Elife* **6**.

1089 Soares, H., Henriques, R., Sachse, M., Ventimiglia, L., Alonso, M.A., Zimmer, C., Thoulouze, M.I., and
1090 Alcover, A. (2013). Regulated vesicle fusion generates signaling nanoterritories that control T cell
1091 activation at the immunological synapse. *J Exp Med* **210**, 2415-2433.

1092 Stamberger, H., Weckhuysen, S., and De Jonghe, P. (2017). STXBP1 as a therapeutic target for epileptic
1093 encephalopathy. *Expert Opin Ther Targets* **21**, 1027-1036.

1094 Sudhof, T.C. (2004). The synaptic vesicle cycle. *Annual review of neuroscience* **27**, 509-547.

1095 Sudhof, T.C. (2013). Neurotransmitter release: the last millisecond in the life of a synaptic vesicle.
1096 *Neuron* **80**, 675-690.

1097 Sudhof, T.C., and Rothman, J.E. (2009). Membrane fusion: grappling with SNARE and SM proteins.
1098 *Science* **323**, 474-477.

1099 Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth,
1100 A., Santos, A., Tsafou, K.P., *et al.* (2015). STRING v10: protein-protein interaction networks, integrated
1101 over the tree of life. *Nucleic Acids Res* **43**, D447-452.

1102 Teschemacher, A.G., and Seward, E.P. (2000). Bidirectional modulation of exocytosis by angiotensin II
1103 involves multiple G-protein-regulated transduction pathways in chromaffin cells. *J Neurosci* **20**, 4776-
1104 4785.

1105 Thul, P.J., Akesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., Asplund, A., Bjork,
1106 L., Breckels, L.M., *et al.* (2017). A subcellular map of the human proteome. *Science* **356**.

1107 Tonks, N.K. (2006). Protein tyrosine phosphatases: from genes, to function, to disease. *Nature reviews*
1108 *Molecular cell biology* **7**, 833-846.

1109 Umahara, M., Okada, S., Yamada, E., Saito, T., Ohshima, K., Hashimoto, K., Yamada, M., Shimizu, H.,
1110 Pessin, J.E., and Mori, M. (2008). Tyrosine phosphorylation of Munc18c regulates platelet-derived
1111 growth factor-stimulated glucose transporter 4 translocation in 3T3L1 adipocytes. *Endocrinology* **149**,
1112 40-49.

1113 Vilar, S., Cozza, G., and Moro, S. (2008). Medicinal chemistry and the molecular operating environment
1114 (MOE): application of QSAR and molecular docking to drug discovery. *Curr Top Med Chem* **8**, 1555-1572.

1115 Wang, H.M., Xu, Y.F., Ning, S.L., Yang, D.X., Li, Y., Du, Y.J., Yang, F., Zhang, Y., Liang, N., Yao, W., *et al.*
1116 (2014). The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation
1117 and ubiquitination barcodes. *Cell Res* **24**, 1067-1090.

Wang, Y., Vachon, E., Zhang, J., Cherepanov, V., Kruger, J., Li, J., Saito, K., Shannon, P., Bottini, N., Huynh, H., *et al.* (2005). Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. *J Exp Med* 202, 1587-1597.

Wei, C.H., Kao, H.Y., and Lu, Z. (2013). PubTator: a web-based text mining tool for assisting biocuration. *Nucleic Acids Res* 41, W518-522.

Wu, L.G., Hamid, E., Shin, W., and Chiang, H.C. (2014). Exocytosis and endocytosis: modes, functions, and coupling mechanisms. *Annu Rev Physiol* 76, 301-331.

Yang, X., Wang, S., Sheng, Y., Zhang, M., Zou, W., Wu, L., Kang, L., Rizo, J., Zhang, R., Xu, T., *et al.* (2015). Syntaxin opening by the MUN domain underlies the function of Munc13 in synaptic-vesicle priming. *Nat Struct Mol Biol* 22, 547-554.

Yu, X., Chen, M., Zhang, S., Yu, Z.H., Sun, J.P., Wang, L., Liu, S., Imasaki, T., Takagi, Y., and Zhang, Z.Y. (2011). Substrate specificity of lymphoid-specific tyrosine phosphatase (Lyp) and identification of Src kinase-associated protein of 55 kDa homolog (SKAP-HOM) as a Lyp substrate. *The Journal of biological chemistry* 286, 30526-30534.

Yu, Z.H., and Zhang, Z.Y. (2018). Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases. *Chemical reviews* 118, 1069-1091.

Zhang, D., Marlin, M.C., Liang, Z., Ahmad, M., Ashpole, N.M., Sonntag, W.E., Zhao, Z.J., and Li, G. (2016). The Protein Tyrosine Phosphatase MEG2 Regulates the Transport and Signal Transduction of Tropomyosin Receptor Kinase A. *J Biol Chem* 291, 23895-23905.

Zhang, D.L., Sun, Y.J., Ma, M.L., Wang, Y.J., Lin, H., Li, R.R., Liang, Z.L., Gao, Y., Yang, Z., He, D.F., *et al.* (2018). Gq activity- and beta-arrestin-1 scaffolding-mediated ADGRG2/CFTR coupling are required for male fertility. *Elife* 7.

Zhang, S., Liu, S., Tao, R., Wei, D., Chen, L., Shen, W., Yu, Z.H., Wang, L., Jones, D.R., Dong, X.C., *et al.* (2012). A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes. *J Am Chem Soc* 134, 18116-18124.

Zhao, W.D., Hamid, E., Shin, W., Wen, P.J., Krystofiak, E.S., Villarreal, S.A., Chiang, H.C., Kachar, B., and Wu, L.G. (2016). Hemi-fused structure mediates and controls fusion and fission in live cells. *Nature* 534, 548-552.

Zhou, Z., Misler, S., and Chow, R.H. (1996). Rapid fluctuations in transmitter release from single vesicles in bovine adrenal chromaffin cells. *Biophysical journal* 70, 1543-1552.

FIGURE LEGENDS

Figure 1. Inhibition of PTP-MEG2 reduced the spike amplitude and ‘foot’ probability of catecholamine secretion.

(A-D). The epinephrine (A-B) or norepinephrine (C-D) secreted from the adrenal medulla was measured after stimulation with high KCl (70 mM) (A,C) or Angiotensin II (AngII, 100 nM) (B,D) for 1 min, with or without pre-incubation with a specific PTP-MEG2 inhibitor (400 nM) for 1 hours. Data were obtained from 6 independent experiments and displayed as the mean $\pm$ SEM. ***, $P < 0.001$: cells stimulated with KCl or AngII compared with un-stimulated cells. #, $P < 0.05$; ##, $P < 0.01$; ###, $P < 0.001$: cells pre-incubated with PTP-MEG2 inhibitors compared with control vehicles. All the data were analyzed using Student's t-test.

(E-F). Ang II (100 nM) induced amperometric spikes by primary mouse chromaffin cells after incubation with PTP-MEG2 inhibitor at different concentrations.

(G). The distribution of the quantal size of AngII (100 nM)-induced amperometric spikes by primary chromaffin cells after incubation with different concentrations of PTP-MEG2 inhibitor. Histograms show the number of amperometric spikes of different quantal sizes.

(H and I). Secretory vesicles of primary chromaffin cells were examined by transmission electron microscopy before or after 100 nM AngII stimulation, with or without pre-incubation with 400 nM Compound 7. Scale bars: H, I, 150 nm. Red arrows indicate morphologically docked LDCVs and green arrows stands for undocked LDCVs. PM represents plasma membrane.

(J). Vesicle numbers according to different distances from the plasma membrane were calculated in the presence or absence of 100 nM AngII or 400 nM Compound 7. PM stands for plasma membrane.

(K). The percentage of vesicles with different diameters was measured after 100 nM AngII stimulation or incubation with 400 nM Compound 7. Compound 7 significantly decreased vesicle size under AngII stimulation. (J)- (K) *, ** and *** indicate $P < 0.05$, $P < 0.01$ and $P < 0.001$, respectively, between cells stimulated with AngII compared with un-stimulated cells. ### indicate $P < 0.001$ between incubated with the control vehicles and cells incubated with Compound 7. N.S. means no significant difference. All the data were analyzed using Student's t-test.

(L). The percentage of pre-spike foot (PSF) (left panel) and stand-alone foot (SAF) (right panel) were calculated after incubation with the indicated concentrations of Compound 7. # indicates incubation with the indicated concentrations of Compound 7 compared with the subgroup with AngII and without Compound 7. # indicates $P < 0.05$ and ### indicates $P < 0.001$. All the data were analyzed using one-way ANOVA.

Figure 2 Interaction of PTP-MEG2 and tyrosine-phosphorylated NSF in the medulla and the crystal structure of the PTP-MEG2/phospho-NSF-segment complex.

(A). NSF was phosphorylated after stimulation with AngII or KCl. Adrenal medulla cells were

stimulated with 100 nM AngII or 70 mM KCl for 5 min and lysed. NSF was immunoprecipitated with a specific NSF antibody coated with Protein A/G beads. A pan-phospho-tyrosine antibody pY²⁰ was used in Western blotting to detect the tyrosine-phosphorylated NSF in the adrenal medulla under different conditions.

(B). NSF was co-localized with PTP-MEG2 in the adrenal medulla. After stimulation with 100 nM AngII, NSF and PTP-MEG2 in the adrenal medulla were visualized with immunofluorescence. White arrow stands for co-localization of the PTP-MEG2 and NSF.

(C). Analysis of PTP-MEG2 and NSF fluorescence intensities by Pearson's correlation analysis. The Pearson's correlation coefficient was 0.7.

(D). Phosphorylated NSF interacted with PTP-MEG2. PC12 cells were transfected with FLAG-NSF. After stimulation of the cells with 100nM AngII, the potential PTP-MEG2 substrate in cell lysates was pulled down with GST-PTP-MEG2-D⁴⁷⁰A or GST control.

(E). The overall structure of PTP-MEG2-C⁵¹⁵A/D⁴⁷⁰A in complex with the NSF-pY⁸³ phospho-segment.

(F). The 2Fo-Fc annealing omit map (contoured at 1.0σ) around the NSF-pY⁸³ phospho-segment.

(G). Plot of distance RMSDs of individual residues between the crystal structures of the PTP-MEG2/NSF-pY⁸³ phospho-peptide complex (PDB:6KZQ) and the PTP-MEG2 native protein (PDB:2PA5).

(H). Superposition of the PTP-MEG2/NSF-pY⁸³ phospho-peptide complex structure (red) on the PTP-MEG2 native protein structure (PDB:2PA5, blue). The structural rearrangement of the WPD loop and β3-loop-β4 is highlighted.

(I and J). The closure of the WPD loop and corresponding conformational changes in the inactive state (I) and the active state (J) of PTP-MEG2. The rotation of R⁵²¹ leads to the movement of W⁴⁶⁸ and a corresponding 7 Å movement of the WPD loop.

(K and L). The structural rearrangement of β3-loop-β4 of PTP-MEG2 in the active state (L) compared with the inactive state (K). The disruption of the salt bridge between E⁴⁰⁶ and R⁵²¹ contributed to the new conformational state of the N-terminal of β3-loop-β4.

(M and N). The conformational change of the P-loop of the inactive state (M) and the active state of PTP-MEG2 in response to NSF-pY⁸³ segment binding (N). The disruption of the charge interaction between R⁴⁰⁹ and D³³⁵ resulted in the movement of the main chain from G⁴⁰⁸ to K⁴¹¹.

Figure 3. Molecular determinants of PTP-MEG2 interaction with the NSF-pY⁸³ site.

(A). Schematic representation of interactions between PTP-MEG2 and the NSF-pY⁸³ site.

(B). Relative values of the decreased phosphatase activities of different PTP-MEG2 mutants towards pNPP (p-Nitrophenyl phosphate) compared with wild-type PTP-MEG2.

(C). Fold-change decreases in the phosphatase activities of different PTP-MEG2 mutants towards the NSF-pY⁸³ phospho-segment compared with wild-type PTP-MEG2. The red column indicates that the mutation sites have greater effects on the enzyme activities toward phospho-NSF segment than the PNPP. The green column indicates that the mutation sites only have significant effects on the enzyme activity toward NSF phospho-segment but not pNPP. The white column stands for the mutants that have similar effects on pNPP and NSF phospho-segment.

(D). Sequence alignment of PTP-MEG2 from different species and with other PTP members. Important structural motifs participating in phosphatase catalysis or the recognition of the NSF-pY⁸³ site are shown, and key residues contributing to the substrate specificity are highlighted. *** P<0.001; PTP-MEG2 mutants compared with the control. Data were obtained from 3 independent experiments. N.S. means no significant difference. All the data were analyzed using one-way ANOVA.

Figure 4. The tip opening of the pY+1 pocket is critical for PTP-MEG2 substrate specificity.

(A). Surface representations of the complex structures of PTP-MEG2-C⁵¹⁵A/D⁴⁷⁰A/NSF-pY⁸³, PTP1B-C²¹⁵A/EGFR-pY⁹⁹² (PDB:1EEN), LYP-C²²⁷S/SKAP-HOM-pY⁷⁵ (PDB:3OMH), PTPN18-C²²⁹S/HER2-pY¹²⁴⁸ (PDB:4GFU), and PTP-STEP/pY (PDB:2CJZ). Crystal structures of PTP-MEG1 (PDB:2I75), SHP1 (PDB:4HJQ), PTPH1 (PDB:4QUN) and SHP2 (PDB:3B7O). The pY+1 sites are highlighted.

(B). Summary of the distance between the C β atoms of D³³⁵ and Q⁵⁵⁹ (corresponding to PTP-MEG2 number) of the pY+1 pocket in PTP-MEG2 and other classical non-receptor PTPs bearing the same residues at similar positions.

Figure 5. Effects of different PTP-MEG2 mutants on properties of catecholamine secretion from primary chromaffin cells.

(A). Primary mouse chromaffin cells were transduced with a lentivirus containing the gene for wild-type PTP-MEG2 or different mutants with a GFP tag at the C-terminus. Positive transfected cells were confirmed with green fluorescence and selected for electrochemical analysis. Typical amperometric current traces evoked by AngII (100 nM for 10 seconds) in the control (transduced with control vector) (top left panel), WT (top right panel), G³³⁴R (bottom left panel), and D³³⁵A (bottom right panel) are shown.

(B). The schematic diagram shows key residues of PTP-MEG2 defining the substrate specificity adjacent to the pY⁸³ site of NSF.

(C). The distribution of the quantal size of chromaffin cells transduced with lentivirus

containing the genes encoding different PTP-MEG2 mutants.

(D). Statistical diagram of the quantal size in Fig. 5A. The secretion amount of each group was standardized with respect to the control group.

(E-G). Calculated parameters of secretory dynamics, including the spike amplitude (E), PSF frequency (F), and SAF frequency (G).

D-G, * indicates PTP-MEG2 mutants overexpression group compared with the WT overexpression group. # indicates the overexpression group compared with the control group. **, $P < 0.01$; ***, $P < 0.001$ and #, $P < 0.05$; ##, $P < 0.01$; ### $P < 0.001$. N.S. means no significant difference. All the data were analyzed using one-way ANOVA.

Figure 6. Identification of potential candidate substrates of PTP-MEG2 that participate in fusion pore initiation and expansion.

(A). Flowchart for the workflow to predict the candidate substrates of PTP-MEG2 during fusion pore initiation and expansion. A total of 54 proteins were enriched with the functional protein association network STRING and the text mining tool PubTator by searching the keywords “fusion pore”, “secretory vesicle” and “tyrosine phosphorylation”. These proteins were filtered with UniProt by selecting proteins located only in the membrane or vesicle, which resulted in 28 candidates. The Human Protein Atlas database was then applied to exclude proteins with no expression in the adrenal gland. Finally, we used the post-translational-motif database PhosphoSitePlus to screen candidate proteins with potential phospho-sites that matched our sequence motif prediction at the pY+1 or pY+2 positions.

(B). After the bioinformatics analysis, a total of 12 candidate PTP-MEG2 substrates that may participate in fusion pore initiation and expansion and their potential phospho-sites were displayed.

(C). The GST pull-down assay suggested that PACSIN1, MUNC18-1, VAMP7, SNAP25, DYNAMIN1 and DYNAMIN2 directly interact with PTP-MEG2. PC12 cells were transfected with plasmids of candidate substrates, including SYN1, MUNC18-3, PACSIN1, SCAMP1, MUNC18-1, PPP3CA, STX17, VAMP7, SYT7, SYT11, SNAP25, DYNAMIN 1, and DYNAMIN2 stimulated with 100 nM AngII. The tyrosine phosphorylation of these proteins was verified by specific anti-pY antibodies (Supplemental Fig. 9A-E). The potential substrates of PTP-MEG2 in cell lysates were pulled down with a GST-PTP-MEG2-D⁴⁷⁰A trapping mutant and then detected by Western blotting. White arrow stands for Western blot band consistent with the predicted molecular weight of the potential PTP-MEG2 substrate.

(D-F). Co-immunostaining assays of PTP-MEG2 with potential substrates in the adrenal medulla. MUNC18-1, VAMP7 and DYNAMIN2 all showed strong co-localization with PTP-MEG2 after 100 nM AngII stimulation in the adrenal medulla. White arrow stands for co-

localization of PTP-MEG2 with MUNC18-1 or VAMP7. The Pearson's correlation coefficients for D, E and F were 0.61, 0.65 and 0.79 respectively. The co-immunostaining results of PTP-MEG2 with other potential substrates are shown in Supplemental Fig. 8.

Figure 7. Dephosphorylation of MUNC18-1 at the pY¹⁴⁵ site by PTP-MEG2 determines the “foot” probability of catecholamine secretion from chromaffin cells.

(A). Structural representation and location of MUNC18-1-Y¹⁴⁵ in the complex structure of MUNC18-1-SYNTAXIN1 (PDB: 3PUJ).

(B). Detailed structural representation of Y¹⁴⁵ and its interacting residues. Y¹⁴⁵ of MUNC18-1 interacts with the main chain carboxylic oxygen of residues I⁵³⁹ and G⁵⁶⁸ and forms hydrophobic interactions with L⁶, I⁵³⁹, L¹⁴⁷, L¹⁷⁹, L¹⁸³, and L²³⁰ to tether the arc shape of the three domains of MUNC18-1 (PDB: 3PUJ).

(C). Association analysis of SNPs of MUNC18-1 with human disease.

(D). Interactions of the PTP-MEG2-trapping mutants with the MUNC18-1-Y¹⁴⁵ mutants and DYNAMIN2-Y¹²⁵ mutants. PC12 cells were transfected with FLAG-MUNC18-1-Y¹⁴⁵, FLAG-DYNAMIN2-Y¹²⁵ and different mutations of the FLAG-MUNC18-1-Y¹⁴⁵ A, Y¹⁴⁵H, Y¹⁴⁵E or Y¹⁴⁵F mutants, FLAG-DYNAMIN2-Y¹²⁵ A, Y¹²⁵E, Y¹²⁵F mutants, 24 hours before stimulation with 100 nM AngII, respectively. The cell lysates were then incubated with GST-PTP-MEG2-D⁴⁷⁰A for 4 hours with constant rotation. The potential PTP-MEG2 substrates were pulled down by GST-beads, and their levels were examined by the FLAG antibody with Western blotting.

(E). Primary chromaffin cells were transduced with lentivirus containing the gene encoding wild-type MUNC18-1 or different mutants. These cells were stimulated with 100 nM AngII. The amperometric spikes were detected with CFE. Typical amperometric traces are shown.

(F). The percentages of pre-spike foot for wild-type MUNC18-1 or different mutants were calculated.

(G). The percentages of stand-alone foot for wild-type MUNC18-1 or different mutants were calculated.

(H). The MUNC18-1-Y¹⁴⁵ mutation decreased the interaction between MUNC18-1 and SYNTAXIN1. PC12 cells were transfected with plasmid encoding SYNTAXIN-1. The proteins in cell lysates were pulled down with purified GST-MUNC18-1-Y¹⁴⁵ and the GST-MUNC18-1-Y¹⁴⁵H/E/F, and detected with SYNTAXIN1 antibody. The right histogram shows the quantified protein levels.

(I). Primary chromaffin cells were transduced with lentivirus containing the gene encoding wild-type DYNAMIN2 or different mutants. These cells were stimulated with 100 nM AngII. The amperometric spikes were detected with CFE. Typical amperometric traces are shown.

(J). The percentages of pre-spike foot for wild-type DYNAMIN2 or different mutants were

calculated.

(K). The percentages of stand-alone foot for wild-type DYNAMIN2 or different mutants were calculated.

(L). Plasmids encoding DYNAMIN2 (DYNAMIN2-WT, DYNAMIN2-Y¹²⁵E or DYNAMIN2-Y¹²⁵F) and LYN-YFP, AT1aR-C-RLUC were co-transferred into HEK293 cells at 1:1:1 ratio. The BRET experiment was performed to monitor the mutation effects of DYNAMIN2 on AT1aR endocytosis in response to AngII (1μM) stimulation.

(M). A GTPase assay was performed on His-DYNAMIN2-WT (500ng), His-DYNAMIN2-Y¹²⁵E (500ng), His-DYNAMIN2-Y¹²⁵F (500ng). Purified DYNAMIN2 proteins were incubated with 5μM GTP in the presence of 500μM DTT for 90 minutes, followed by addition of GTPase-Glo™ Reagent and detection reagent. The luminescence were measured after 37-mins incubation. Bar representation of the results from six independent experiments.

(N). Phosphorylated Y¹²⁵ of DYNAMIN2 was identified by LC-MS/MS. The PTP-MEG2-DA trapping mutant was used to pull down potential PTP-MEG2 substrates from the adrenal lysates after AngII stimulation. Trypsin-digested potential PTP-MEG2 substrates were subjected to LC-MS/MS analysis. The doubly charged peptide with m/z 725.06 matches VYSPHVLNLTLDLPGITK of DYNAMIN2 with Y¹²⁵ phosphorylation.

F-H, J-M * indicates MUNC18-1, DYNAMIN2 mutants overexpression group compared with the WT overexpression group. # indicates MUNC18-1, DYNAMIN2 overexpression group compared with the control group. *, P<0.05; **, P<0.01; *** P<0.001 and #, P<0.05; ##, P<0.01; ### P<0.001. N.S. means no significant difference. All the data were analyzed using one-way ANOVA.

Figure 8. The structural details of the PTP-MEG2-MUNC18-1-Y¹⁴⁵ interaction and catalytic bias of PTP-MEG2 towards NSF-pY⁸³ and MUNC18-1-pY¹⁴⁵

(A). The 2Fo-Fc annealing omit map (contoured at 1.0σ) around MUNC18-1-pY¹⁴⁵ phospho-segment.

(B). Comparison of residues of PTP-MEG2 interacting with NSF and MUNC18-1. Amino acid residues of NSF and MUNC18-1 are coloured as follows: green, residues interacting with both NSF and MUNC18-1; red, residues specifically contributing to NSF recognition; blue, residues selectively contributing to MUNC18-1 interaction.

(C). The structural alteration of the interactions surrounding Y⁴⁷¹ of PTP-MEG2 with the MUNC18-1-pY¹⁴⁵ site.

(D). The structural alteration of the interactions surrounding I⁵¹⁹ of PTP-MEG2 with the MUNC18-1-pY¹⁴⁵ site.

(E). Relative phosphatase activities of different PTP-MEG2 mutants towards the MUNC18-1-

pY¹⁴⁵ phospho-segment compared with wild-type PTP-MEG2.

(F). Relative phosphatase activities of different PTP-MEG2 mutants towards the DYNAMIN 2-pY¹²⁵ phospho-segment compared with wild-type PTP-MEG2. E-F Residues are coloured according to Figure 8B.

(G).The percentages of PSF and SAF for PTP-MEG2-R⁴⁰⁹A or R⁴¹⁰A were calculated.

(H). Schematic illustration of the PTP-MEG2-regulated processes of vesicle fusion and secretion in chromaffin cells via the dephosphorylation of different substrates with distinct structural basis. PTP-MEG2 regulates vesicle fusion and vesicle size during the catecholamine secretion of adrenal gland by modulating the phosphorylation state of the pY⁸³ site of NSF, which relies on the key residues G³³⁴, D³³⁵ (pY loop), Y⁴⁷¹ (WPD loop), I⁵¹⁹ (P-loop) and Q⁵⁵⁹ (Q loop). PTP-MEG2 regulates the fusion pore initiation and expansion procedures of catecholamine secretion by the adrenal gland (also designated as foot probability) by modulating the newly identified substrate MUNC18-1 at its pY¹⁴⁵ site and DYNAMIN2 at its pY¹²⁵, through distinct structural basis from that of its regulation of NSF phosphorylation. E-F, * P<0.05, * P<0.01, *** P<0.001; PTP-MEG2 mutants compared with the control. N.S. means no significant difference. Data were obtained from 3 independent experiments. All the data were analyzed using one-way ANOVA.

1395 **Table -1 Crystallographic Data and Refinement Statistics**

Data Collection	PTP-MEG2 · NSF pY ⁸³ Peptide	PTP-MEG2 · MUNC18-1 pY ¹⁴⁵ Peptide
Space group	p2 ₁ 2 ₁ 2	p2 ₁ 2 ₁ 2
Cell Dimensions		
a (Å)	71.447	71.048
b (Å)	83.708	84.074
c (Å)	48.615	48.753
α (deg)	90	90
β (deg)	90	90
γ (deg)	90	90
Resolution (Å)	80-1.70(1.76-1.70) ^a	54.3-2.08(2.08-2.20) ^a
Unique observations	32748(3167) ^a	18019(1773) ^a
Completeness (%)	99.6(98.3) ^a	99.8(99.8) ^a
Redundancy	3.8(3.8) ^a	6.1(6.3) ^a
<I>/<σ>	22.22(2.34) ^a	6.5(2.3) ^a
R _{merge}	0.064(0.477) ^a	0.191(0.927) ^a
Structure Refinement	80-1.70	
Resolution (Å)	1.70	2.08
Reflections used for R _{work} /R _{free}	31212/1536	17995/896
R _{work} /R _{free} ^b (%)	0.1900/0.2173	0.2102/0.2304
Average B-factor		
Protein	20.98	35.36
Peptide	31.525	53.25
RMSD ideal bonds (Å)	0.008	0.008
RMSD ideal angles (deg)	1.212	0.968
RamachandranPlot (%)		
Most favored	93.73	93.56
Allowed	4.88	6.10
Generously allowed	1.39	0.34
Disallowed	0	0

1396

1397 ^a Each dataset was collected from a single crystal.

1398 The values in parentheses correspond to the highest resolution shell.

Figure 1

Figure 2

Figure 3

A

B

C

D

D

	pY loop		β3-β4 loop		WPD loop	P loop	Q loop			
	331	338	408	411	469	472	517	521	556	562
hPTP-MEG2	NRYGDVPC		GRR		PDYG		AGIGR		FSIQ	TPE
bPTP-MEG2	NRYGDVPC		GRR		PDYG		AGIGR		FSIQ	TPE
rPTP-MEG2	NRYGDVPC		GRR		PDYG		AGIGR		FSIQ	TPE
mPTP-MEG2	NRYGDVPC		GRR		PDYG		AGIGR		FSIQ	TPE
hPTP-MEG1	NRYRDISP		GRVK		PDHG		AGIGR		MMIQ	TPS
hPTP1B	NRYRDVSP		GSLK		PDFG		AGIGR		GLIQ	TAD
hTCTPTP	NRYRDVSP		ESVK		PDFG		AGIGR		GLIQ	TPD
hPTPH1	NRYKDVLP		GRTK		PDHG		AGIGR		MMVQ	TSS
hSTEP	NRYKTILP		MNEK		PDQK		AGIGR		GMIQ	TCE
hSHP-1	NRYKNILP		GRNK		PDHG		AGIGR		GMVQ	TEA
hSHP-2	NRYKNILP		GKSK		PDHG		AGIGR		GMVQ	TEA
hHePTP	DRYKTILP		GKEK		PDHQ		AGIGR		GMIQ	TAE
hPEST	NRYKDILP		GRKK		PDHD		AGCGR		SAVQ	TKE
hLYP	NRYKDILP		GKKK		PDHD		AGCGR		SLVQ	TQE
hBDP1	NRYKDVLP		GRKR		PDHG		AGCGR		AAVQ	TEE

Figure 4

A

B

Complex	PDB code	pY+1	Distance(C β)	
PTP-MEG2/NSF(pY83)		T	10.42	D335:Q559
PTP1B/EGFR(pY992)	1EEN	L	11.46	D48:Q262
LYP/SKAP-HOM(pY75)	3OMH	D	11.32	D63:Q274
PTPN18/HER2(pY1248)	4GFU	L	11.89	D64:Q276
PTP-STEP/pY	2CJZ		12.43	N312:Q516
PTP-MEG1	2I75		11.16	D687:Q896
SHP1	4HJQ		12.27	N278:Q500
PTPH1	4QUN		12.35	D678:Q886
SHP2	3B7O		12.44	N281:Q506

Figure 5

Figure 6

Figure 7

Figure 8